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Abstract:
Cancer chemotherapy responses have been related to multiple 
pharmacogenetic biomarkers, often for the same drug. This study utilizes 
machine learning to derive multi-gene expression signatures that predict 
individual patient responses to specific tyrosine kinase inhibitors, 
including erlotinib, gefitinib, sorafenib, sunitinib, lapatinib and imatinib. 
Support Vector Machine learning was used to train mathematical models 
that distinguished sensitivity from resistance to these drugs using a 
novel systems biology-based approach. This began with expression of 
genes previously implicated in specific drug responses, then expanded to 
evaluate genes whose products were related through biochemical 
pathways and interactions. Optimal pathway-extended support vector 
machines predicted responses in patients at accuracies of 70% 
(imatinib), 71% (lapatinib), 83% (sunitinib), 83% (erlotinib), 88% 
(sorafenib) and 91% (gefitinib). These best performing pathway 
extended models demonstrated improved balance predicting both 
sensitive and resistant patient categories, with many of these genes 
having a known role in cancer etiology. Ensemble ML-based averaging of 
multiple pathway extended models derived for an individual drug 
increased accuracy to >70% for erlotinib, gefitinib, lapatinib, and 
sorafenib. Through incorporation of novel cancer biomarkers, machine 
learning-based pathway extended signatures display strong efficacy 
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Cancer chemotherapy responses have been related to multiple pharmacogenetic 
biomarkers, often for the same drug. This study utilizes machine learning to derive multi-
gene expression signatures that predict individual patient responses to specific tyrosine 
kinase inhibitors, including erlotinib, gefitinib, sorafenib, sunitinib, lapatinib and imatinib. 
Support Vector Machine learning was used to train mathematical models that 
distinguished sensitivity from resistance to these drugs using a novel systems biology-
based approach. This began with expression of genes previously implicated in specific 
drug responses, then expanded to evaluate genes whose products were related through 
biochemical pathways and interactions. Optimal pathway-extended support vector 
machines predicted responses in patients at accuracies of 70% (imatinib), 71% 
(lapatinib), 83% (sunitinib), 83% (erlotinib), 88% (sorafenib) and 91% (gefitinib). These 
best performing pathway-extended models demonstrated improved balance predicting 
both sensitive and resistant patient categories, with many of these genes having a known 
role in cancer etiology. Ensemble machine learning-based averaging of multiple pathway-
extended models derived for an individual drug increased accuracy to >70% for erlotinib, 
gefitinib, lapatinib, and sorafenib. Through incorporation of novel cancer biomarkers, 
machine learning-based pathway-extended signatures display strong efficacy predicting 
both sensitive and resistant patient responses to chemotherapy. 
Keywords: tyrosine kinase inhibitors, biochemical pathways, systems biology, machine 
learning, gene signatures




Selection of a chemotherapy regimen is largely determined by efficacy of a drug in eligible 
subjects for a specific type and stage of cancer, and considers duration, location and 
magnitude of responses.1 Individuals progress to second-line chemotherapeutic agents 
after demonstrating or developing limited efficacy to or after relapse from first-line 
chemotherapeutics.2,3 It is feasible to consider personal differences in genomic responses 
as a means of differentiating between acceptable chemotherapies with otherwise similar 
response rates across populations of eligible patients.4
Previously, we developed gene signatures that predict patient responses to specific 
chemotherapies from gene expression (GE) and copy number (CN) levels in a set of 
distinct breast and/or bladder cancer cell lines,5 with each line characterized by the drug 
concentration that inhibited growth by half (GI50).6,7 Support vector machine (SVM) and 
random forest machine learning (ML) models were built for each drug using expression 
and/or copy number values from ‘curated genes’ with evidence from published cancer 
literature of a contribution to the function or response to said drug in cell lines or patients. 
This paper develops signatures for tyrosine kinase inhibitors (TKIs),8 for which literature 
on genes associated with response is somewhat more limited. 
We developed a novel technique for generating biochemically inspired gene signature 
models by expanding the pool of genes for ML to include genes both possessing and 
lacking literature support. The premise for including novel genes or gene products in 
these models is that these candidates could be related to genes supported by 
documented evidence through biochemical pathways or interactions that also contribute 
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to drug response. We then compare conventional ML-based gene signatures to 
corresponding pathway-extended (PE) versions for these TKIs.
Abnormal expression levels or mutations in tyrosine kinases are often causally related to 
tumour angiogenesis9 and metastasis10 in certain cancers.11,12 TKIs have emerged as 
effective anti-cancer therapies, owing to their activity by ATP-competitive inhibition of the 
catalytic binding site of these kinases.13 Despite a conserved mechanism of action, 
sorafenib, sunitinib, erlotinib, gefitinib, imatinib and lapatinib preferentially inhibit different 
tyrosine kinase targets and exhibit distinct pharmacokinetic profiles.13–15 Sorafenib and 
sunitinib both inhibit VEGFRs, PDGFRs, FLT3R, RET and c-Kit.15,16 However, structural 
differences produce different binding profiles. For example, in binding VEGFR, sorafenib 
stabilizes the DFG-out inactive conformation of the enzyme, which allows it to bind within 
an allosteric pocket,17 whereas sunitinib binds in and around the ATP-binding region, 
imparting lower kinase selectivity and faster off-rates.18 Similarly, erlotinib and gefitinib 
are both preferential inhibitors of EGFR, and share analogous chemical structure;19,20 but 
post-absorption, gefitinib is localized to a greater extent in tumour tissue, while erlotinib 
preferentially accumulates in plasma.21 Imatinib is particularly selective for the ABL 
kinase8,22,23 while lapatinib binds to both EGFR and ERBB2.24 The specificities of TKIs 
for different tyrosine kinase targets and the relative activities of those targets in different 
tumour types largely determine which of these drugs are recommended to treat individual 
clinical indications. These include renal cell carcinoma (sunitinib, sorafenib), 
hepatocellular carcinoma (sorafenib), pancreatic cancer (erlotinib), lung cancer (erlotinib, 
gefitinib), breast cancer (lapatinib) and chronic myelogenous leukemia (imatinib). 
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Tumor cells can exhibit intrinsic or acquired resistance to chemotherapy. Intrinsic 
responses refer to an inherent capability to suppress the effects of treatment or render 
treatment cytostatic to functional characteristics of these cells. In acquired resistance, the 
tumor mutates or undergoes epigenetic changes after an initial period of clinical success 
that renders it impervious to treatment.25,26 Cytostasis is often achieved by inhibition of 
glycolytic activity with signal transduction, with the largest group of drugs targeting 
tyrosine kinases.27 On average, tumors initially responsive to TKI treatments such as 
erlotinib and gefitinib will progress again within a year of treatment.28,29 Intrinsic resistance 
to these TKI drugs tends to be uncommon in EGFR-positive tumors.30
Recent studies have revealed novel pathways of resistance and sensitivity to 
chemotherapeutic drugs.31,32 This study aimed to generate models that comprehensively 
represent global drug responses by inclusion of novel genes or gene products 
discoverable through their interactions with gene products known to influence these 
responses. We modify supervised ML-based models to systematically identify novel 
biomarkers whose expression is related to GI50. Gene expression changes in cancer cell 
lines that expand conventional gene signatures beyond an initial curated set of genes are 
utilized, including or replacing the initial set with other genes that interact with them. The 
resulting signatures aim to improve accuracy of prediction of individual patient responses 
to chemotherapies targeted towards tyrosine kinases.
2. Methods
2.1 Data and preprocessing of cell line and cancer patient datasets
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Microarray GE, CN, and GI50 values of breast cancer cell lines treated with erlotinib, 
gefitinib, imatinib, lapatinib, sorafenib and sunitinib (obtained from Daemen et al. 
[2013]reference [Ref.] )5) were used to derive ML-based gene signatures that predict drug 
responses. The median GI50 values for these cell lines were applied as the threshold 
distinguishing sensitivity from resistance during ML. The median and range of GI50 values 
for erlotinib was 4.71 [4.18 - 6.54]; gefitinib was 5.03 [4.48 – 6.45]; imatinib was 4.69 [3.82 
– 5.81]; sorafenib was 4.27 [3.0 – 5.83]; and sunitinib was 5.23 [4.70 – 5.98]).5,6 For 
lapatinib, the threshold was set at the GI50 value with the maximum difference relative to 
adjacent cell lines (4.94 [ranges from 4.78 to 6.40]), since the GI50 of multiple cell lines 
were equal to the median value. 
Performance of these gene signatures was assessed using published studies of cancer 
patients treated with these drugs. NCBI Gene Expression Omnibus (GEO; 
https://www.ncbi.nlm.nih.gov/geo/) sourced datasets contained GE data and linked 
clinical outcomes of each patient with non-small cell lung carcinoma (NSCLC; GSE61676, 
N=43)33 treated with erlotinib [in combination with bevacizumab], hepatocellular 
carcinoma (GSE109211, N=67)34 treated with sorafenib, breast cancer (GSE66399, 
N=31)35 treated with lapatinib [‘Arm B’ patient set only, which received lapatinib in 
combination with paclitaxel, fluorouracil, epirubicin and cyclophosphamide], chronic 
myelogenous leukemia (GSE14671, N=23)36 treated with imatinib, breast cancer patients 
(GSE33658, N=11)37 treated with gefitinib [in combination with anastrozole and 
fulvestrant], and gliomas (GSE51305, N=18)38 treated with sunitinib. Each of these 
studies provided clinical information that included a treatment outcome measure that 
could then be utilized as a binary outcome measure for comparison with predictions made 
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by various models. These outcome measurements vary from study to study. For patients 
treated with sorafenib or imatinib, a chemotherapy response biomarker was used to 
distinguish sensitive from resistant patients. For patients treated with erlotinib or lapatinib, 
outcome (i.e. survival vs death) was used as a surrogate for response. Cancer cell 
migration data distinguished patients sensitive vs. resistant to sunitinib (where those with 
‘moderate induction’ or ‘moderate inhibition’ were defined as resistant, and those with 
‘strong inhibition’ were considered sensitive to the drug). Responses to gefitinib were 
classified based on Response Evaluation Criteria In Solid Tumors (RECIST) guidelines 
(where those with progressive disease are considered TKI resistant).39
Patient selection criteria differed between studies. In the GSE61676 study (erlotinib), 
patient data was acquired from the SAKK 19/05 trial, where selection criteria consisted of 
patients with newly diagnosed or recurr nt Stage IIIB or Stage IV NSCLC.33 In the 
sorafenib study (GSE109211), tumour tissue was collected from the STORM trial, which 
enrolled patients with hepatocellular carcinoma with complete radiological response after 
surgical resection or local ablation.34 The lapatinib study (GSE66399) utilized data from 
the CHER-LOB study, where female adults with HER2+ breast cancer were selected.35 
In the GSE33658 patient cohort, CD34+ cells were isolated from peripheral blood 
collected from newly diagnosed chronic-phase chronic myelogenous leukemia patients 
treated with imatinib.36 In the gefitinib study (GSE33658), biopsies were taken from 
postmenopausal women with newly diagnosed ER+ breast cancer receiving anastrozole, 
fulvestrant and gefitinib.37 In the sunitinib study (GSE51305), native glioma tissue 
samples were collected from patients with a diagnosis of high-grade glioma WHO (World 
Health Organization) grade III or IV who underwent surgical resection.38 
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Different expression microarray platforms were used in these GEO datasets, for example, 
GSE66399, GSE61676 and GSE51305 each measure GE values with distinct vendor 
and gene sets. To minimize batch effects and apply the cell-line based signatures to these 
patient datasets, the data were first normalized on a common scale using quantile 
normalization, according to our previously published approach.40 If multiple microarray 
probes existed for the same gene, the mean of all probe measurements were determined.
2.2 Multiple factor analysis and gene set expansion
Genes associated with therapeutic response or function were curated from previous peer-
reviewed publications for each TKI (refer to Additional References). Inclusion criteria were 
based on evidence of the gene or protein contributing to pharmacokinetic or 
pharmacodynamic response, or were established biomarkers of sensitivity or resistance. 
Multiple Factor Analysis (MFA) was performed using cell line expression and GI50 
(concentration of drug inhibiting 50% growth) data5 for each curated gene using the 
MFAPreselection software we have developed (available in a Zenodo archive41). The 
archive describes the algorithm used by MFAPreselection to traverse pathway networks, 
dataflow within the program, and software code. MFA determines the relationship 
between GI50 and GE and/or CN data for all expressed genes as an angle that indicates 
the degree to which expression or copy number correlates either directly (~ zero degrees) 
or inversely (~180 degrees) with the GI50 of the set of cell lines.42,43 Circular plots, 
generated by MFAPreselection, indicate this correlation angle (Figure 1).43 
MFAPreselection searches for known gene pseudonyms and substitutes the correct alias 
(from www.genecards.org [downloaded July 2016]). In the Daemen et al. dataset5 used 
for training in SVM learning (see below), the microarray platform data was in some 
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instances labeled with conflicting gene names. During pathway extension, associated 
genes were related to older gene aliases that have been deprecated and reassigned by 
HUGO (Human Genome Organization) Gene Nomenclature Committee to other 
unrelated genes. This led to some spurious associations between genes during pathway 
extension. Examples include: PPY which was mismatched due to its former alias ‘PNP’ 
as well as DDR2 due to incorrect association with its former alias ‘TKT’. For the sorafenib 
model PE-Sor, associations of GC to CNN1 and CA3 were eliminated due to its original 
designation as ‘DBP’, however its associations between HNF1A, CYP11B1, CYP27B1, 
and PIK3R3 remained valid (Figure S1). This issue was addressed using a program script 
that removed these unsupported associations from the output of MFAPreselection.41 
 A Perl script was written to eliminate these spurious matches by confirming relations 
reported by MFAPreselection with the PathwayCommons Interaction SIF (Simple 
Interaction Format) file ("Parentage-MFA-Path-Source-Program.Simple-Output-
Version.pl"; provided in a Zenodo archive41). If corrected labels were not found or a gene 
was absent from a microarray platform, then this cell line or gene is not included in the 
analysis. 
ML signatures were expanded by MFAPreselection to include genes associated with 
curated genes by extension using components of adjacent biochemical pathways 
(pathway-extension, or PE; Figure S2). To identify these relationships, MFAPreselection 
relied on the PathwayCommons database (version 8 [downloaded April 2016]) to assess 
expanded gene lists by inclusion of genes addressable from the curated set (one node 
distant from a curated gene), followed by a second iteration (two nodes distant from a 
curated gene; illustrated in Figure 1). During this process, genes that did not meet 
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minimally-defined levels of MFA correlation to drug GI50 (either positive or negative) were 
discarded and additional gene expansion steps also ignored these genes. These levels 
were determined using six different conditions set for the MFAPreselection software: 
maximum thresholds up to 10° and 20° from either full direct or inverse correlation for 
curated genes only (conditions #1 and 2, respectively); up to a 10° and 20° threshold for 
both curated genes and directly related genes (one-node distant; conditions #3 and 4, 
respectively); and up to a 10° and 20° threshold for curated genes and genes up to two 
nodes distant from the curated gene set (conditions #5 and 6, respectively). Genes in 
which GI50 was correlated with CN (Tables S1 [A-F]) were not considered for SVM 
analyses due to unavailability of CN data in patient datasets.
2.3 SVM learning
Genes with expression levels correlated with GI50 were qualified for SVM analysis. SVMs 
were used to train GE datasets against GI50 data using the MATLAB statistics toolbox 
(similar to the procedure described in Mucaki et al. [2016]Ref. 44 using SVM software 
developed in Zhao et al. [2018]Ref. 40; software available at: 
doi:10.5281/zenodo.1170572). Instead of using the “fitcsvm” function (as in Ref.Mucaki 
et al. [2016] 44), a multiclass-compatible “fitcecoc” function was used to generate SVM 
signatures, with both misclassification rate44 and log loss40 value used as performance 
metrics to derive optimal signature models. A forward feature selection (FFS) algorithm 
was used to generate these gene signatures (program from Zhao et al. [2018]40: 
“FFS_strat_kfold_gridsearch.m”). FFS tests each gene at random from the qualified gene 
set by training a cross-validated Gaussian kernel SVM on the training data to determine 
the individual gene that produces the lowest misclassification rate or log loss value. 
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Subsequent genes are then added to determine whether model performance is improved, 
until the performance criterion converges to a minimum value. Models were built using a 
range of C and sigma values (from 1 to 100,000, in multiples of 10 for each variable 
[where C ≥ sigma]; 21 total combinations). Since the goal of pathway extension was to 
expand and improve these models beyond curated signatures with ≥ 2 genes, PE-derived 
gene signatures with fewer than two genes were excluded from proceeding to the 
validation step. 
2.4 Validation of Cell-Line Derived Gene Signatures using Patient Data
All derived multi-gene SVMs were validated against clinical patient data using traditional 
validation (MatLab program “regularValidation_multiclassSVM.m’ from Ref.Zhao et al. 
[2018] 40). Performance was indicated by both overall predictive accuracy and by 
Matthews Correlation Coefficient (MCC, which assesses overall quality of a binary 
classifier by considering the balance of true and false positives and negatives). Overall, 
the best-performing gene signature for each drug was selected by MCC, as it is a metric 
not skewed by imbalanced data. Once the best performing SVM for each drug was 
established, leave-one-out cross-validation7 was used to determine the overall impact of 
each individual gene to the model itself (change in misclassification or log loss), as well 
as its impact on the accuracy of the model to predict chemotherapy response. Top-
performing PE TKI models can be accessed to predict responses based on expression in 
individual patients with our web-based SVM calculator 
(http://chemotherapy.cytognomix.com).6
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Ensemble averaging of multiple SVM models involved weighting patient predictions from 
highest performing models derived for a particular TKI by the area under the curve (AUC) 
of each corresponding model (computed using the MATLAB function ‘perfcurve’). MCC 
itself was also evaluated as a potential source of weights for ensemble averaging; 
however, AUC-weighted predictions were superior in overall performance. The number 
of models included in the ensemble varied, as the number of highest performance models 
for each TKI differed (4 for sorafenib; 2 for erlotinib, sorafenib, imatinib, sunitinib and 
gefitinib). A patient was considered resistant to a drug if the sum of all AUC-weighted 
predictions were > 0 and sensitive if this sum was < 0.
3. Results
3.1 Generating SVM signatures using breast cancer cell line-training data
Genes associated with drug response or function were curated for gefitinib (N=113), 
sunitinib (N=90), erlotinib (N=71), imatinib (N=157), sorafenib (N=73), and lapatinib 
(N=91) (curated genes are provided in Table S1 and labeled as ‘0’ node distant genes). 
In general, MFA was performed using 48 breast cancer cell lines using GE, CN and GI50 
values for each gene.5 Biochemically inspired ML-based signatures for each TKI, derived 
from curated genes, were obtained according to our previously described approach.6 
MFA analysis was also performed on genes encoding proteins related to these curated 
genes (through interaction or as neighbours in the same biochemical pathway) to identify 
those that also correlated, either directly or inversely, with GI50 (all GI50-correlated PE 
genes are provided in Table S1 [labeled as 1-node and 2-node distant genes]). This 
expanded set of GI50-correlating genes were then used to derive SVMs containing 
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combinations of curated and PE genes. The derived signatures for each TKI minimized 
either misclassification or log loss to generate the best performing models. The best 
performing curated and PE SVM signatures for erlotinib [C-Erl, PE-Erl], sorafenib [C-Sor, 
PE-Sor], gefitinib [C-Gef, PE-Gef], lapatinib [C-Lap, PE-Lap], imatinib [C-Ima, PE-Ima], 
and sunitinib [C-Sun, PE-Sun] are summarized in Table 1, whereas the performance of 
all models is indicated in Table S2. 
3.2 Validation of cell line-based SVM signatures using cancer patient data
Cell line-derived SVMs for TKIs were initially evaluated on patient data sets where 
patients were treated with the same agent.40 Erlotinib signatures were validated using 
patients with NSCLC (GSE61676; N=9 survived, 34 died), sorafenib signatures were 
validated using patients with hepatocellular carcinoma (GSE109211; N=21 sensitive, 46 
resistant), sunitinib signatures were validated using outcomes of patients with high-grade 
gliomas (GSE51305; N=6 sensitive, 12 resistant), imatinib signatures were validated 
using outcomes of patients with chronic myelogenous leukemia (GSE14671; N=17 
sensitive, 6 resistant), and lapatinib and gefitinib signatures were validated based on 
breast cancer outcomes (GSE66399 [N=8 survived, 23 died] and GSE33658 [N=10 
sensitive, 2 with resistant], respectively). 
MCC (range -1 to +1) was the primary determinant of model performance, as it measures 
overall accuracy (OA) while accounting for representation between binary prediction 
categories.45 This was necessary, as patient datasets available exhibited imbalances in 
the ratios of responsive to non-responsive patients in terms of their respective observed 
clinical outcomes. Models based on features generated under relaxed constraints 
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(condition #6) generated the best performing SVM on patient data for every TKI, except 
sorafenib. The best-performing PE model was PE-Sor, which accurately predicted patient 
responses with 0.72 MCC (and 88% OA). The best performing curated model was Cur-
Lap, with 0.31 MCC (and 77% OA). In comparison to curated SVMs, PE SVMs predicted 
patient response with 0.26 higher MCC and 33% higher OA (13% increase in accuracy 
predicting sensitive patients; 13% increase in accurately predicting resistant patients). 
Except for imatinib, the best-performing PE model outperformed their curated 
counterpart. This difference in performance is evident in Figure 2, as predictive accuracy 
for PE models is consistently higher for both resistant and sensitive patient outcomes.
The erlotinib (GSE61676) and gefitinib (GSE33658) studies utilized for model testing 
provide patient GE data both pre- and post-treatment. This provided an opportunity to 
determine whether to determine whether short term drug exposure altered GE and model 
accuracy. For erlotinib, blood samples were obtained prior to and 24 hours post-
treatment. For gefitinib, biopsies were taken prior to and 3 weeks post-treatment. Both 
PE-Erl and PE-Gef exhibited slightly lower performance for the pre-treatment samples 
(Table S3), with 5 additional patients misclassified with PE-Erl (73% OA with N=43 total 
patients) and 2 additional misclassified individuals with PE-Gef (73% OA; N=12 patients). 
MCC for PE-Gef is significantly lower (-0.15), since the model misclassifies all untreated 
individuals as resistant. Treatment with these drugs perturbs predictions, but to a limited 
extent.
3.3 Composition of PE SVM signatures and contributions of individual features
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PE SVM signatures contain either genes from peer-reviewed literature about the drug 
response (“initial” or “curated” genes), those related to these genes through direct 
interactions or as neighbours within the same pathways (one-node distant genes), or 
genes associated with these one-node distant genes (two-node distant genes). To better 
comprehend the composition of and relationships between genes in the best-performing 
PE SVM signatures, we analyzed the connection networks for each model (see Table S4 
for connection network for all other top performing PE models). For example, while PE-
Sor consists of one curated gene and eight two-node distant genes, there are an 
additional 6 curated and 10 one-node genes that connect the genes in PE-Sor by 
pathway-extension (Figure 3A shows a two-dimensional visualized connection network 
for this drug; see Figures 3B-F for lapatinib, gefitinib, sunitinib, imatinib and erlotinib, 
respectively). Due to the complexity of the relationships between gene products 
for erlotinib, it was not feasible to create an unequivocal two-dimensional network 
diagram for this drug response, and is instead presented in tabular form (Figure 3F). 
Nevertheless, it is apparent from the majority of these network diagrams that genes that 
were two-nodes distant from the curated gene set were most commonly selected in the 
best performing PE models. Furthermore, the two-node distant genes selected interacted 
with multiple curated or one-node distant genes.
To determine the degree to which each gene in a signature contributed to the accuracy 
of the overall model prediction, we performed leave-one-out cross-validation for each 
gene in the best-performing model for each drug. We then reassessed the predictions of 
the resultant signature for the observed responses in the cell lines used for model training 
(Table S5) and for the patient data used for testing (Figure 4). Based on patient data, the 
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gene features eliminated from models that had the highest impact on performance were: 
CDK6, BAG2, SULT1E1, and IL1RN (PE-Erl); CNTN1, GCG and NTRK3 (PE-Gef); 
GRB7 and BCAT (PE-Lap); ELF5, TGFB1, PRKD2, RBP5, and GC (PE-Sor); EPHA2 
and SIAE (PE-Sun); and CACNA2D1 and GRM3 (PE-Ima). Genes removed that 
improved predictive performance on patient data included FBP1 (PE-Lap), PLAT (PE-
Sor) and LHX8 (PE-Sor).
PE-Gef consists of 4 pathway-extended genes (CNTN1, CXCL2, NTRK3 and GCG) and 
one curated gene, GCG. GCG encodes a hormone preprotein which is cleaved into four 
peptides, including glucagon-like peptide 2, which has been found to reduce gefitinib-
induced intestinal atrophy in mice.46 Removal of NTRK3 from PE-Gef had the largest 
impact on model performance, reducing MCC to 0. NTRK3 has a critical role in secretory 
breast cancer gene, with the EVT6-NTRK3 fusion oncogene being considered a primary 
initiating event.47,48 
PE-Sun, which consists of three pathway-extended genes, SIAE, NR4A1, and EPHA2, 
was evaluated in gliomas. NR4A1 is essential for colony formation of glioblastoma cells 
on soft agar.49 Of 14 glioblastoma specimens, 13 possessed elevated EPHA2 levels.50 
Removal of NR4A1 from PE-Sun did not alter overall accuracy or MCC of the model, 
while removal of EPHA2 decreased overall accuracy by 55% and MCC by 0.94. 
Regarding SIAE, alterations in cell surface sialylation by glucocorticosteroids has been 
suggested to promote glioma formation.51   
PE-Sor (COL25A1, TGFB1, DACT1, RBP5, PRKD2, GC, ELF5, LHX8, and SCNN1A) 
was used to predict sorafenib response in hepatocellular carcinoma (HCC) patients. 
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Removal of RBP5, PRKD2, GC and ELF5 significantly reduced overall accuracy (>50%) 
and MCC (>0.7) (Figure 4A). RBP5 is linked to aggressive tumour features in HCC,52 
PRKD2 is upregulated in HCC and correlated with metastasis,53 and decreased actin-free 
GC levels have been found to relate with disease severity in HCC.54,55 Vitamin D3, which 
is bound by GC, lowers the effective dose of sorafenib required for its cytostatic effect in 
melanoma and differentiated thyroid carcinoma.56 ELF5 has not been direct connected to 
HCC, but has been associated with a wide range of cancers.57,58 Genes in PE-Sor that 
have not been as strongly linked to cancer (COL25A1 and LHX8) did not change model 
accuracy to the same extent (<10%) when removed (Figure 4A). Removal of the curated 
gene TGFB1, which enhances the apoptotic activity and sensitizes cells to sorafenib59 
decreased overall accuracy by 60% in HCC patients. The respective contexts of the 
curated Sorafenib-related genes juxtaposed with the PE genes in PE-Sor are indicated 
in a cellular schematic of the roles and functions of these genes (Figure 5). 
PE-Ima (LIF, MRGPRF, GRM3, TNNI1, and CACNA2D1) predicted imatinib response in 
chronic myelogenous leukemia patients. LIF encodes a protein which prevents continued 
growth of myeloid leukemia cells by inducing terminal differentiation,60 although 
independent removal of LIF did not notably affect model performance. Downregulation of 
CACNA2D1 from PE-Ima is associated with erythroid differentiation of K562 and KCL-22 
chronic myeloid leukemia cells.61 Removal of CACNA2D1 decreased both classification 
accuracy and MCC (-44% and -0.18, respectively; Figure 4E). 
A second PE model (indicated in green in Figure 4E) exhibited comparable performance 
to PE-Ima: TNNI1 and WASF3 [C=10000, σ=10000], with an OA of 57% (47% accurate 
with sensitive and 83% with resistant patients; MCC = 0.27). WASF3 has been implicated 
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in breast cancer metastasis.62 TNNI1, a gene that is shared by both this model and PE-
Ima, is one of the three inhibitory subunits of smooth muscle troponin, that are all 
overexpressed in breast cancer.63 Interestingly, the kinase, TNNI3K, that phosphorylates 
this protein is essential for proliferation of mononuclear diploid cardiomyocytes during 
heart muscle repair due to injury.64 Phosphorylation of troponin would appear to have a 
previously uncharacterized moonlighting function in tumor development.65 If imatinib 
inhibits TNNI3K through an off-target effect, this may modulate TNNI1 activation and 
possibly, an associated proliferative phenotype. 
PE-Lap (FBP1, ITGA11, TRIM68, BCAT1, ZNF780A, UTP20, and GRB7) predicted 
outcomes of breast cancer patients treated with lapatinib. Independent removal of BCAT1 
reduced accuracy in predicting sensiti e patients. Silencing or knockdown of BCAT1 has 
been associated with reduced growth of triple negative breast cancer.66 Removal of 
ITGA11 or TRIM68 did not alter PE-Lap accuracy (Figure 4B). 
PE-Erl consisted of NEK7, SLCO3A1, RELB, FRMD4A, HSD17B2, CDK6, PALM, IL1RN, 
SMYD1, BAG2, GNG3, and SULT1E1, and was used to predict chemotherapy response 
in NSCLC patients. BAG2 and SULT1E1 are novel biomarkers of erlotinib efficacy, as 
removal of either gene led to imbalanced predictions of sensitive patients by this 
signature. Overexpression of BAG2 has been associated with poor disease-specific 
survival in lung cancer,67 while the SULT1E1 polymorphism rs4149525 has been 
associated with shortened overall survival in NSCLC.68 This model originally contained 
PLAT, which when eliminated from the erlotinib dataset of 43 patients significantly 
increased in overall accuracy (+10%) and MCC (+0.21) of the model predictions (Figure 
4F). PLAT was therefore considered a false positive result from ML, and therefore 
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eliminated from gene signature. Our post-hoc analysis demonstrated that the majority of 
genes (75%) in PE-Erl were associated with the NSCLC phenotype. 
3.4 Performance of PE SVM signatures on sex-stratified patients
Previous studies have suggested that females may be more sensitive to TKI treatment 
than males.69,70 We therefore stratified TKI model performance by sex in the GSE61676 
data set, which provided patient sex information along with response (19 male [3 
sensitive] and 24 female [6 sensitive] patients). Considering all patients, PE-Erl predicted 
patient response with an MCC of 0.41 and 83% overall accuracy (42% and 93% accurate 
in patients sensitive and resistant to this drug, respectively). In males alone, PE-Erl’s 
overall accuracy was lower (76%), with MCC notably decreased to 0.11, as PE-Erl did 
not predict individuals who were sensitive or resistant to the drug as accurately (27% and 
85%, respectively). In females, PE-Erl performed better than for the full data set, with 
85% OA (MCC = 0.56), of which resistance was predicted with 99% accuracy and 
sensitivity was predicted with 42% accuracy (Table S6). This indicates that the PE-Erl 
signature more precisely captures factors that contribute to greater sensitivity in females.  
The predictive performance of erlotinib PE model PE-Erl to the NSCLC dataset 
GSE61676 was higher in female patients than male patients (0.45 greater MCC; 9% 
greater OA). This was consistent with the possibility that PE-Erl contains gene(s) 
distinguishing sex-differentiated sensitivity to the drug. Of the 12 genes comprising PE-
Erl, independent removal of RELB and CDK6 features from the model notably reduced 
accuracy of the predicted response in female patients that were sensitive to the drug. 
RELB has previously been identified as a sex-discriminatory candidate gene in 
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trichostatin A-treated chronic lymphocytic leukemia cells due to repressed expression in 
resistant male cells, but upregulation in resistant female cells.71 RELB also possesses 
pro-survival functions across multiple cancer types72–74 and has been identified as a 
prognostic biomarker for NSCLC patients.75 Overall, RELB is a top candidate gene to 
explain the improved accuracy of PE-Erl in female NSCLC patients. 
3.5 AUC-weighted ensemble model predictions 
Ensemble learning consolidates hypotheses of multiple models to potentially improve 
predictive performance.76 For ensemble learning, each model’s AUC was computed and 
used to weigh predictions made for each model within the ensemble.77 There were 4 
SVMs for sorafenib possessing strong predictive accuracy with patient derived expression 
data. Therefore, all were used for ensemble averaging. For the other TKIs, ensemble 
learning combined the top- and second-best performing SVMs (Table 2). Ensemble 
averaging improved both OA and MCC for erlotinib (OA: 84% [+1%]; MCC – 0.45 [+0.04]), 
and sorafenib (OA: 91% [+3%]; MCC: 0.79 [+0.07]). For patients with the same predicted 
outcome in ≥75% of cases after ensemble learning, overall accuracy exceeded 80% for 
all TKIs except lapatinib. Discordant consensus predictions between multiple signatures 
for the same drug (majority outcome occurred <75% for each patient) exhibited lower 
overall accuracy. 
4. Discussion 
Pathway-extended GE signatures generally improved accuracy of predicted patient 
responses to specific TKIs. Compared to signatures comprised solely of literature curated 
genes, PE signatures revealed previously unknown gene loci that contributed to drug 
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response and, on average, had consistently better predictive performance. Aside from 
higher OA, the prediction accuracy for both sensitive and resistant patient groups 
(measured by MCC) was consistently more balanced. For example, Cur-Lap was the 
sole curated model with higher OA than its PE counterpart; however, its predictions were 
more skewed resulting in lower MCC. Furthermore, both MCC and overall accuracy were 
increased by AUC-weighted ensemble averaging of multiple PE models for sorafenib, 
erlotinib and imatinib. Except for lapatinib, the highest OAs were evident in patients 
receiving a ‘consensus’ prediction (where ≥75% of predictions made by the models in the 
ensemble predicted the same outcome for a patient). The improved predictive 
performance of PE SVMs, both individual and as ensembles of models, suggests that the 
genes within these signatures may refine the predominant mechanisms of both sensitivity 
and resistance to TKI therapy. PE gene models may be more useful in selecting 
chemosensitivity regimens for patients compared to models solely consisting of 
previously implicated genes known to respond to a specific chemotherapy. 
Pathway-extension and the inclusion of pathway-related genes allowed for a larger pool 
of genes involved in ML. We avoided overfitting78 by pre-filtering these genes based on 
correlation with GI50. Furthermore, independent validation was determined by the identity 
and expression level of these features in patients treated with these drugs. Signatures 
containing pathway-related genes produced higher performing SVM signatures, 
consistent with the possibility that optimal molecular indicators of chemo-response may 
identify genes upstream or downstream of, or are interactors with, previously known 
cancer biomarkers. Generating SVMs from curated genes assures that features selected 
do not arise from statistical association alone. Generating PE SVMs required systematic 
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selection of genes with established relationships to curated genes. For the best-
performing PE gene signatures, most signature genes validated in the present study had 
been independently associated with abnormalities of expression, copy number or 
mutation in these tumour types (Additional References). Expanded signatures could 
potentially assist in the identification of novel biomarkers of chemo-response in these 
tissues.
Primary and secondary genes in PE gene signatures can offer context for drug responses 
without predicate literature support. The relationships between curated genes and genes 
selected through pathway-extension for sorafenib are illustrated in Figure 5. The vitamin 
D transporter encoded by GC is a major determinant of the response to this drug, as 
overall prediction accuracy is decreased by 52% upon its removal from PE-Sor (Figure 
4A). In fact, GC is two nodes distant from multiple curated genes (ABCB1, ABCC2 and 
HNF1A, among others [Figure 3A]). The ABCB1 transporter has been implicated in 
sorafenib-related toxicities based on efflux efficiency.79,80 ABCB1 also carries out efflux 
of Vitamin D3,81 and the 1,25-dihydroxy-vitamin D3 isoform (or 1.25D) activates ABCB1 
expression.82 Vitamin D is converted to this 1.25D isoform by CYP27B1, which is one-
node distant from ABCB1. Similarly, GC binds specifically to 1.25D, which puts GC one 
node distant from ABCB1. The growth inhibitory effect of sorafenib has been shown to be 
amplified by 1.25D.56 Together, these network connections provide context that integrates 
functions and roles of individual genes of the tumour response to sorafenib. The PE 
signatures will be useful for understanding drug toxicity, although it was not explicitly a 
goal of this study. The importance of GC in PE-Sor may explain why a lower sorafenib 
dose is effective for treatment. Supplemental vitamin D3 reduces toxicity to sorafenib at 
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this lower dose in differentiated thyroid carcinoma that is non-responsive to iodine 
therapy.56 
The best performing SVMs for TKIs shared several common genetic pathways. Multiple 
PE models contained genes related to NOD-like receptor signaling (erlotinib: NEK7, 
RELB), PI3K-AKT signaling pathway (erlotinib: CDK6, GNG3; lapatinib: ITGA11; 
sunitinib: EPHA2, NR4A1) and Ras-Raf-MEK-ERK pathway (erlotinib: CDK6, RELB; 
sorafenib: TGFB1; sunitinib: EPHA2, NR4A1). Aberrant NOD-like receptor signaling 
drives carcinogenesis,83 while numerous cancer therapies target either or both of PI3K 
and AKT.84–86 The Ras-Raf-MEK-ERK pathway involves several protein kinases activated 
by tyrosine kinase receptors, with oncogenic mutations most prominently affecting Ras 
and B-Raf within the pathway.87 These pathways, which are disrupted broadly among 
different cancers, are implicated across numerous high performing ML models predicting 
TKI response.
Several pathway-extended (EPHA2, PRKD2, and PDGFRB) and curated (CDK6 and 
ABL2) gene products extrapolated from the highest performing signatures were bound to 
kinases based on a proteomic analysis of target selectivity for 243 kinase-inhibitors on 
259 distinct tyrosine kinases.88 Few tyrosine kinase target genes from this proteomic 
analysis for TKIs in the current study exhibited correlations between GI50 and either gene 
expression or copy number (< 20° threshold; Table S7). RET was the only SVM gene 
implicated in the response to a TKI for both gene expression and protein (sorafenib; 
Concentration- and Target-Dependent Selectivity of 0.515; Klaeger et al. [2017]Ref. 88). 
Therefore, expression of genes that are either positively or inversely correlated with drug 
response is generally unrelated to quantification of proteins that directly interact with the 
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kinases themselves. If absence of signature genes from those corresponding to 
proteomic analysis is not attributable to either experimental or specific cell lines used, 
then signature gene expression is more likely indirectly regulated by gene products that 
are selective for most TKIs. Many genes in the PE SVMs were two nodes distant from 
curated biomarkers, which is consistent with the possibility that these represent common 
control points in the regulation of drug responses. In this regard, such control points 
exhibit behavior similar to state-cycle attractors of self-organizing systems.89 From a ML 
perspective, the dimensionality of the SVM model is reduced, avoiding overfitting, by 
substituting these control point genes for curated genes. Improvement in the prediction 
accuracy for both the sensitive and resistant patient categories might also be a 
consequence of these biomarkers being control points for multiple curated genes. 
Consider two curated genes that are "controlled" or regulated by the same two node 
biomarker, where inclusion of one of these improves accuracy for detecting drug 
sensitivity, and the other improves detection of resistance. Substituting the controlling 
gene for both curated genes in the PE-signature might improve accuracy of detection of 
both outcomes.  
Transferability of these cell line-based models to other independent cell line datasets was 
also evaluated.90 PE TKI models were analyzed using data from the Sanger Genomics of 
Drug Sensitivity in Cancer Project (GDSC), including RNA-seq derived cancer cell line-
derived gene expression data (E-MTAB-3983; ArrayExpress) based on IC50 values of cell 
lines in CancerRxGene.91 Using median IC50 to distinguish sensitivity from resistance, the 
top SVM that we derived for each TKI could not significantly separate cell lines sensitive 
and resistant to the same drug in GDSC (MCC from 0 to 0.19; OA ranging from 50-58%). 
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Altering the IC50 thresholds did not significantly change these results. Applying this 
analysis to cell lines from specific tissues used in the derivation of the specific TKI 
signatures, PE-Ima was more accurate for seven imatinib-treated cell lines derived from 
intestinal tumours (OA of 69%; MCC – 0.41). The disparity in performance between the 
training and testing data sets may be related to differences in the expression patterns in 
different tissue types, or batch effects. IC50 measurements for the same cell line and drug 
are known to vary significantly between studies, especially when the cell line is drug 
insensitive,92 which may contribute to the poor correlation between results of both 
datasets. 
Transferability of SVMs to different patient datasets may also be confounded by several 
other limitations of applying ML models derived from cell line expression to predict 
responses to the same drugs using patient GE data. By contrast with tumours, cancer 
cell lines tend to have a stable genetic profile when grown under controlled culturing 
conditions. Consequently, they tend to lack the genetic heterogeneity present in many 
tumour types,93 particularly during progression, which often occurs concomitant with 
evolution of acquired chemotherapy resistance.94 Cancer cell lines also lack extracellular 
matrix, which contributes to tumour growth, migration and invasion in vivo. These 
differences may challenge prediction accuracy of cell line-based SVMs using patient GE 
and/or CN. Clinical outcome measures within patient data sets were not consistent 
between different studies of the same tumour type. Finally, the cell line GE data used for 
training originated in this study solely from breast cancer, whereas patient tumour GE 
data were also derived from other cancer types. 
5. Conclusions
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The enhanced performance of chemotherapy response models developed using 
pathway-extension (over curated-only models) suggests that an interaction between a 
drug and its target may not directly relate with drug response; sensitivity could also be 
caused by a cellular event downstream of the drug-target interaction. PE models derived 
in this study demonstrated strong efficacy in selecting relevant genes, identifying novel 
molecular biomarker candidates, and predicting patient responses to TKIs. Strong-
performing PE models appear to predict chemotherapy response in a cancer-type specific 
fashion, as many pathway-related genes selected by SVM software as novel candidate 
biomarkers of TKI efficacy were already prognostic biomarkers for the cancer type 
patients within the testing set were afflicted with. Ensemble averaging of multiple PE 
SVMs improved predictive accuracy in most cases and were found to be most commonly 
correct when predictions were highly consistent across each model constituting the 
ensemble. PE-Erl was also shown to have greater accuracy when considering solely 
female NSCLC patients. Interestingly, RELB, a feature in this signature, had previously 
demonstrated sexually dimorphic expression upon cancer treatment. The process of 
including pathway-related genes in biochemically inspired gene signatures can produce 
highly specific and accurate SVMs. PE models may have practical value, both in 
identifying novel biomarkers of chemosensitivity and in selecting effective 
chemotherapeutic agents. 
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Table 1. Performance of Curated SVMs and PE Models on Training and Patient Testing Data
Performance / Accuracy
Validation TrainingTKI
(Patient Tumor Type; 
GEO Dataset)
Model Gene Signature (SVM: C; σ)
MCC Sensitive Resistant Overall Log Loss Misclass-ification




NEK7, SLCO3A1, RELB, FRMD4A, HSD17B2, 
CDK6, PALM, IL1RN, SMYD1, BAG2, GNG3, 
SULT1E1 (1000; 100)
0.41 42% 93% 83% 0.01 -




ELF5, RBP5, GC, PRKD2, SCNN1A, 
COL25A1, TGFB1, DACT1, LHX8 (100000; 
1000)
0.72 72% 95% 88% 0.05 -
Cur GRP (10000; 10) 0.16 13% 100% 29% 0.53 -Gefitinib
(Breast Cancer; 
GSE33658) PE CNTN1, CXCL2, NTRK3, GCG (10000; 10) 0.67 100% 50% 91% 0.58 -
Cur ERBB2 (10000; 1) 0.31 13% 100% 77% 0.72 -Lapatinib
(Breast Cancer;
GSE66399) PE
FBP1, ITGA11, TRIM68, BCAT1, ZNF780A, 
UTP20, GRB7 (10; 10) 0.33 63% 74% 71% 0.01 -
Cur IL3, ABL2, CDKN1A (10000; 10) 0.23 41% 83% 52% - 0.42Imatinib
(Leukemia; 
GSE14671) PE
LIF, MRGPRF, GRM3, TNNI1, CACNA2D1 
(100000; 100) 0.18 84% 33% 70% - 0.06
Cur HGF, VEGFC, TSC1, AXL, ENPP2, NFKB1 (100000; 10000) 0.31 87% 45% 59% - 0.14
Sunitinib
(Glioma;
GSE51305) PE EPHA2, NR4A1, SIAE (100000; 100000) 0.61 67% 92% 83% - 0.20
Cur - Curated models derived from genes associated with drug in literature; PE - Pathway-extended models; MCC - Matthews Correlation 
Coefficient; Sensitive - Accuracy to Drug Responsive Patients; Resistant - Accuracy to Non-Responsive Patients; Overall - Combined accuracy
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Table 1 - Performance of Curated SVMs and PE Models on Training and Patient Testing Data. Curated 
and PE SVMs were derived for each TKI based on ability sorting cancer cell lines. The C (box-constraint), 
σ (kernel-scale) and features comprising the best-performing model are indicated. Models listed are those 
which exhibited optimal performance, defined as the model with the highest MCC against the patient data 
set. ‘Validation’ indicates the predicted drug response of patients made by each curated and PE model as 
compared to the observed response provided by these studies. ‘Training’ indicates either percent 
misclassification or overall log-loss of the cell line-based model by cross-validation, depending on which 
minimization metric was used in said model derivation.
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Table 2. Models used in the Ensemble Averaging analysis of Patient Data

















1. NEK7, SLCO3A1, RELB, FRMD4A, HSD17B2, CDK6, 




2. RET, HDGF, B3GNT5, BAG2, DSP, CAPN1, MAF, 
BCL2, MAP2K6, RPL13A, PTPRZ1, OLIG2 (10000; 100) 0.47
0.45 44% 94% 84% 89% 57%
1. ELF5, RBP5, GC, PRKD2, SCNN1A, COL25A1, TGFB1, 
DACT1, LHX8 (100000; 1000) 0.88
2. ELF5, RBP5, GC, PRKD2, SCNN1A, GRM7, COL25A1, 
TGFB1, DACT1, LHX8 (100000; 1000) 0.85
3. CPT1C, DOPEY2, KRT26, DGUOK, DLC1, CYP11B1, 




4. FURIN, HTR3D, LAMA1, STMN2, SLITRK3, CACNA1S, 
SCN2A, CCL5, TRIM32 (100000; 100000) 0.93
0.79 81% 96% 91% 94% 83%
1. FBP1, ITGA11, TRIM68, BCAT1, ZNF780A, UTP20, 
GRB7 (10; 10) 0.70
Lapatinib
2. S100A12, API5, GRHL1, TAS1R1, TUBB1, CORO1A 
(100000; 100) 0.56
0.33 63% 74% 71% 55% 80%
1. EPHA2, NR4A1, SIAE (100000; 100000) 0.78Sunitinib
2. SCN3B, MED29, MPST, TSC1, AHR, CARD9, RPL3 
(100000; 100000) 0.79
0.40 83% 58% 67% 91% 29%
1. LIF, MRGPRF, GRM3, TNNI1, CACNA2D1 (100000; 
100) 0.55
Imatinib
2. WASF3, TNNI1 (10000; 10000) 0.65
 0.27 47% 83% 57% 85% 20%
1. CNTN1, CXCL2, NTRK3, GCG (10000; 10) 0.5Gefitinib
2. BDNF, PRKCB (10000; 100) 0.69
0.39 89% 50% 82% 100% 33%
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† Consensus and non-consensus predictions are when the Ensemble predicts the same outcome for a patient ≥ or <75% of the time, respectively
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Table 2 - Models used in the Ensemble Averaging analysis of Patient Data. Ensemble averaging 
amalgamates predictions from numerous SVMs for an individual TKI, weighted by AUC (indicated). Each 
SVM signature included within ensemble averaging predicted the response of each patient treated with its 
associated TKI, and the majority prediction was used of that of the ensemble. Overall, the accuracy of the 
ensemble prediction was equivalent to or greater than any individual model within it.




Figure 1 – Procedure for Pathway Gene Selection. An initial set of genes with known 
associations to a particular TKI (here we show a subset of sorafenib-related genes) are selected 
and then evaluated by MFA, which was used to find a correlation between cell line drug sensitivity 
(GI50) and the GE or CN of these genes in those cell lines (left). MFA correlation circles visualize 
these relationships (bottom). The gene list is extended, using pathway and interaction databases 
(i.e. PathwayCommons) to find genes related to curated genes which showed MFA correlation to 
GI50 (one-node distant genes; middle-left). The list is extended again from the MFA-correlating 
one-node distant genes (two-node distant genes; middle-right). All curated and extended genes 
which showed an MFA correlation were then used as features to generate a final predictive SVM 
gene signature for the evaluated TKI (right). Genes within the best performing sorafenib signature 
are indicated in thick borders (black for curated genes, purple for pathway-extended genes).
 
Figure 2 - Accuracy of Curated and Pathway-Extended SVMs on TKI Sensitive and 
Resistant Patients. The predictive accuracy of the best-performing curated (C-) and Pathway-
Extended (PE-) models for each TKI were arranged based on their accuracy in classification of 
drug sensitive and resistant tumour patients. This illustrates how curated models are often only 
accurate towards one patient class (sensitive or resistant) but not both (red), which is an issue as 
the patient data was often imbalanced (number of sensitive | resistant patients in each study: 
lapatinib [‘Lap’; n= 8 | 23], imatinib [‘Ima’; n= 17 | 6], sunitinib [‘Sun’; n= 6 | 12], erlotinib [‘Erl’; n= 
9 | 34], gefitinib [‘Gef’; n= 10 | 2], and sorafenib [‘Sor’; n= 21 | 46]). Conversely, predictions by PE 
SVMs were often more balanced (blue), possessing moderate to high accuracy for both sensitive 
and resistant patients, and consequently greater accuracy as a whole. 
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Figure 3 - Connection Network for Pathway-Extended TKI SVMs. Schematic relationships 
outlining the pathway connections for the best-performing PE model for each drug in panels A) 
sorafenib; B) lapatinib; C) gefitinib; D) sunitinib; E) imatinib and F) erlotinib. All symbols indicated 
are gene names. The erlotinib model was highly interconnected and is represented as a table. 
Genes in red are features selected for the final PE-Sor gene signature, while genes colored green 
were chosen in a separate PE gene signature with comparable performance. Genes in black were 
not part of the final signature themselves but correlated with efficacy to sorafenib by MFA and 
expanded the gene pool through biochemical connections they possessed to one-node or two-
node distant genes.
Figure 4 – Effect of Removal of Individual Genes from Signature on Overall Accuracy using 
Patient Tumour Data. The patient classification accuracy and MCC of the strongest performing 
PE models are altered upon the removal of each component gene listed. These PE TKI gene 
signatures are: A) sorafenib [PE-Sor]; B) lapatinib [PE-Lap]; C) gefitinib [PE-Gef]; D) sunitinib 
[PE-Sun]; E) imatinib [PE-Ima]; and F) erlotinib [PE-Erl]. Blue and red bars denote the overall 
accuracy and MCC of the model after gene removal, respectively. 
Figure 5 –Schematic of the Pathway-Extended Genes in the Sorafenib Model PE-Sor. The 
best performing sorafenib model PE-Sor is a 9-gene model consists of a single curated gene 
(TGFB1) and eight genes selected by pathway-extension (ELF5, RBP5, GC, PRKD2, SCNN1A, 
COL25A1, DACT1, and LHX8). This cell schematic provides context of the cellular mechanisms 
of action and/or known relationships between genes with a documented impact on sorafenib 
activity (‘curated’ genes; black borders) and those genes selected by pathway extension (purple 
borders). Genes with grey borders are not curated nor pathway-extended genes and are simply 
present to give context between genes and their known cellular functions. Thicker borders specify 
Page 42 of 89MedComm
For Review Only
42
those genes in the PE-Sor model, while gene colour-coding indicates how GE and/or copy 
number correlated to sorafenib GI50 by MFA.
Appendices
Tables S1 - MFA of Gene Expression/Copy Number to GI50 of A) sorafenib; B) gefitinib; C) 
lapatinib; D) erlotinib; E) sunitinib; F) imatinib
Tables S2 - Training and Validation of SVM Signatures Generated for A) sorafenib; B) gefitinib; 
C) lapatinib; D) erlotinib; E) sunitinib; F) imatinib
Table S3 – Predictive Accuracy of PE-Erl and PE-Gef for Test Patients Pre- and Post-Treatment
Table S4 - Connection Pathways for Top-Performing SVM Signatures
Table S5 – Performance of Responses after Gene Removal from SVM Signatures in Cell Lines
Table S6 - Performance of the Strongest Performing Erlotinib SVM Signature Stratified by Sex
Table S7 - MFA Analysis of Genes Implicated in Klaeger et al, 2017
Figure S1 - MFAPreselection Alias Correction for Sorafenib. MFAPreselection software 
features a gene alias check in order to match genes in datasets that may contain deprecated 
gene names which have since been reassigned. During its pathway-extension step, certain gene 
associations were invalid due to gene aliases that are currently used by an unrelated gene. This 
issue was corrected by additional software run after MFAPreselection (see Methods). Left: PE-
Sor connection network without correcting alias gene association issue. Right: After applying 
corrections, associations to CNN1, CA3 and PPY were removed from the connections network. 
Note that all genes that were selected in the PE-Sor model have at least one valid association 
post-correction.
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Figure S2 - MFAPreselection Pathway-Extension Flowchart. This flowchart illustrates how 
MFAPreselection expands an initial set of curated genes (related to the drug of interest) by 
identifying pathway-related genes (using PathwayCommons) that show MFA correlation to drug 
sensitivity.
Additional References. Reference list indicating the studies that describe experimental evidence 
which support the inclusion of genes within the final signature and/or were involved in the 
generation of the final signature. We prioritized studies which showed evidence linking the gene 
to the pharmacokinetics, pharmacodynamics or efficacy of a TKI.
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Cancer chemotherapy responses have been related to multiple pharmacogenetic 
biomarkers, often for the same drug. This study utilizes machine learning to derive multi-
gene expression signatures that predict individual patient responses to specific tyrosine 
kinase inhibitors, including erlotinib, gefitinib, sorafenib, sunitinib, lapatinib and imatinib. 
Support Vector Machine learning was used to train mathematical models that 
distinguished sensitivity from resistance to these drugs using a novel systems biology-
based approach. This began with expression of genes previously implicated in specific 
drug responses, then expanded to evaluate genes whose products were related through 
biochemical pathways and interactions. Optimal pathway-extended support vector 
machines predicted responses in patients at accuracies of 70% (imatinib), 71% 
(lapatinib), 83% (sunitinib), 83% (erlotinib), 88% (sorafenib) and 91% (gefitinib). These 
best performing pathway-extended models demonstrated improved balance predicting 
both sensitive and resistant patient categories, with many of these genes having a known 
role in cancer etiology. Ensemble machine learning-based averaging of multiple pathway-
extended models derived for an individual drug increased accuracy to >70% for erlotinib, 
gefitinib, lapatinib, and sorafenib. Through incorporation of novel cancer biomarkers, 
machine learning-based pathway-extended signatures display strong efficacy predicting 
both sensitive and resistant patient responses to chemotherapy. 
Keywords: tyrosine kinase inhibitors, biochemical pathways, systems biology, machine 
learning, gene signatures




Selection of a chemotherapy regimen is largely determined by efficacy of a drug in eligible 
subjects for a specific type and stage of cancer, and considers duration, location and 
magnitude of responses.1 Individuals progress to second-line chemotherapeutic agents 
after demonstrating or developing limited efficacy to or after relapse from first-line 
chemotherapeutics.2,3 It is feasible to consider personal differences in genomic responses 
as a means of differentiating between acceptable chemotherapies with otherwise similar 
response rates across populations of eligible patients.4
Previously, we developed gene signatures that predict patient responses to specific 
chemotherapies from gene expression (GE) and copy number (CN) levels in a set of 
distinct breast and/or bladder cancer cell lines,5 with each line characterized by the drug 
concentration that inhibited growth by half (GI50).6,7 Support vector machine (SVM) and 
random forest machine learning (ML) models were built for each drug using expression 
and/or copy number values from ‘curated genes’ with evidence from published cancer 
literature of a contribution to the function or response to said drug in cell lines or patients. 
This paper develops signatures for tyrosine kinase inhibitors (TKIs),8 for which literature 
on genes associated with response is somewhat more limited. 
We developed a novel technique for generating biochemically inspired gene signature 
models by expanding the pool of genes for ML to include genes both possessing and 
lacking literature support. The premise for including novel genes or gene products in 
these models is that these candidates could be related to genes supported by 
documented evidence through biochemical pathways or interactions that also contribute 
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to drug response. We then compare conventional ML-based gene signatures to 
corresponding pathway-extended (PE) versions for these TKIs.
Abnormal expression levels or mutations in tyrosine kinases are often causally related to 
tumour angiogenesis9 and metastasis10 in certain cancers.11,12 TKIs have emerged as 
effective anti-cancer therapies, owing to their activity by ATP-competitive inhibition of the 
catalytic binding site of these kinases.13 Despite a conserved mechanism of action, 
sorafenib, sunitinib, erlotinib, gefitinib, imatinib and lapatinib preferentially inhibit different 
tyrosine kinase targets and exhibit distinct pharmacokinetic profiles.13–15 Sorafenib and 
sunitinib both inhibit VEGFRs, PDGFRs, FLT3R, RET and c-Kit.15,16 However, structural 
differences produce different binding profiles. For example, in binding VEGFR, sorafenib 
stabilizes the DFG-out inactive conformation of the enzyme, which allows it to bind within 
an allosteric pocket,17 whereas sunitinib binds in and around the ATP-binding region, 
imparting lower kinase selectivity and faster off-rates.18 Similarly, erlotinib and gefitinib 
are both preferential inhibitors of EGFR, and share analogous chemical structure;19,20 but 
post-absorption, gefitinib is localized to a greater extent in tumour tissue, while erlotinib 
preferentially accumulates in plasma.21 Imatinib is particularly selective for the ABL 
kinase8,22,23 while lapatinib binds to both EGFR and ERBB2.24 The specificities of TKIs 
for different tyrosine kinase targets and the relative activities of those targets in different 
tumour types largely determine which of these drugs are recommended to treat individual 
clinical indications. These include renal cell carcinoma (sunitinib, sorafenib), 
hepatocellular carcinoma (sorafenib), pancreatic cancer (erlotinib), lung cancer (erlotinib, 
gefitinib), breast cancer (lapatinib) and chronic myelogenous leukemia (imatinib). 
Page 48 of 89MedComm
For Review Only
5
Tumor cells can exhibit intrinsic or acquired resistance to chemotherapy. Intrinsic 
responses refer to an inherent capability to suppress the effects of treatment or render 
treatment cytostatic to functional characteristics of these cells. In acquired resistance, the 
tumor mutates or undergoes epigenetic changes after an initial period of clinical success 
that renders it impervious to treatment.25,26 Cytostasis is often achieved by inhibition of 
glycolytic activity with signal transduction, with the largest group of drugs targeting 
tyrosine kinases.27 On average, tumors initially responsive to TKI treatments such as 
erlotinib and gefitinib will progress again within a year of treatment.28,29 Intrinsic resistance 
to these TKI drugs tends to be uncommon in EGFR-positive tumors.30
Recent studies have revealed novel pathways of resistance and sensitivity to 
chemotherapeutic drugs.31,32 This study aimed to generate models that comprehensively 
represent global drug responses by inclusion of novel genes or gene products 
discoverable through their interactions with gene products known to influence these 
responses. We modify supervised ML-based models to systematically identify novel 
biomarkers whose expression is related to GI50. Gene expression changes in cancer cell 
lines that expand conventional gene signatures beyond an initial curated set of genes are 
utilized, including or replacing the initial set with other genes that interact with them. The 
resulting signatures aim to improve accuracy of prediction of individual patient responses 
to chemotherapies targeted towards tyrosine kinases.
2. Methods
2.1 Data and preprocessing of cell line and cancer patient datasets
Page 49 of 89 MedComm
For Review Only
6
Microarray GE, CN, and GI50 values of breast cancer cell lines treated with erlotinib, 
gefitinib, imatinib, lapatinib, sorafenib and sunitinib (obtained from Daemen et al. [2013])5) 
were used to derive ML-based gene signatures that predict drug responses. The median 
GI50 values for these cell lines were applied as the threshold distinguishing sensitivity 
from resistance during ML. The median and range of GI50 values for erlotinib was 4.71 
[4.18 - 6.54]; gefitinib was 5.03 [4.48 – 6.45]; imatinib was 4.69 [3.82 – 5.81]; sorafenib 
was 4.27 [3.0 – 5.83]; and sunitinib was 5.23 [4.70 – 5.98]).5,6 For lapatinib, the threshold 
was set at the GI50 value with the maximum difference relative to adjacent cell lines (4.94 
[ranges from 4.78 to 6.40]), since the GI50 of multiple cell lines were equal to the median 
value. 
Performance of these gene signatures was assessed using published studies of cancer 
patients treated with these drugs. NCBI Gene Expression Omnibus (GEO; 
https://www.ncbi.nlm.nih.gov/geo/) sourced datasets contained GE data and linked 
clinical outcomes of each patient with non-small cell lung carcinoma (NSCLC; GSE61676, 
N=43)33 treated with erlotinib [in combination with bevacizumab], hepatocellular 
carcinoma (GSE109211, N=67)34 treated with sorafenib, breast cancer (GSE66399, 
N=31)35 treated with lapatinib [‘Arm B’ patient set only, which received lapatinib in 
combination with paclitaxel, fluorouracil, epirubicin and cyclophosphamide], chronic 
myelogenous leukemia (GSE14671, N=23)36 treated with imatinib, breast cancer patients 
(GSE33658, N=11)37 treated with gefitinib [in combination with anastrozole and 
fulvestrant], and gliomas (GSE51305, N=18)38 treated with sunitinib. Each of these 
studies provided clinical information that included a treatment outcome measure that 
could then be utilized as a binary outcome measure for comparison with predictions made 
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by various models. These outcome measurements vary from study to study. For patients 
treated with sorafenib or imatinib, a chemotherapy response biomarker was used to 
distinguish sensitive from resistant patients. For patients treated with erlotinib or lapatinib, 
outcome (i.e. survival vs death) was used as a surrogate for response. Cancer cell 
migration data distinguished patients sensitive vs. resistant to sunitinib (where those with 
‘moderate induction’ or ‘moderate inhibition’ were defined as resistant, and those with 
‘strong inhibition’ were considered sensitive to the drug). Responses to gefitinib were 
classified based on Response Evaluation Criteria In Solid Tumors (RECIST) guidelines 
(where those with progressive disease are considered TKI resistant).39
Patient selection criteria differed between studies. In the GSE61676 study (erlotinib), 
patient data was acquired from the SAKK 19/05 trial, where selection criteria consisted of 
patients with newly diagnosed or recurr nt Stage IIIB or Stage IV NSCLC.33 In the 
sorafenib study (GSE109211), tumour tissue was collected from the STORM trial, which 
enrolled patients with hepatocellular carcinoma with complete radiological response after 
surgical resection or local ablation.34 The lapatinib study (GSE66399) utilized data from 
the CHER-LOB study, where female adults with HER2+ breast cancer were selected.35 
In the GSE33658 patient cohort, CD34+ cells were isolated from peripheral blood 
collected from newly diagnosed chronic-phase chronic myelogenous leukemia patients 
treated with imatinib.36 In the gefitinib study (GSE33658), biopsies were taken from 
postmenopausal women with newly diagnosed ER+ breast cancer receiving anastrozole, 
fulvestrant and gefitinib.37 In the sunitinib study (GSE51305), native glioma tissue 
samples were collected from patients with a diagnosis of high-grade glioma WHO (World 
Health Organization) grade III or IV who underwent surgical resection.38 
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Different expression microarray platforms were used in these GEO datasets, for example, 
GSE66399, GSE61676 and GSE51305 each measure GE values with distinct vendor 
and gene sets. To minimize batch effects and apply the cell-line based signatures to these 
patient datasets, the data were first normalized on a common scale using quantile 
normalization, according to our previously published approach.40 If multiple microarray 
probes existed for the same gene, the mean of all probe measurements were determined.
2.2 Multiple factor analysis and gene set expansion
Genes associated with therapeutic response or function were curated from previous peer-
reviewed publications for each TKI (refer to Additional References). Inclusion criteria were 
based on evidence of the gene or protein contributing to pharmacokinetic or 
pharmacodynamic response, or were established biomarkers of sensitivity or resistance. 
Multiple Factor Analysis (MFA) was performed using cell line expression and GI50 
(concentration of drug inhibiting 50% growth) data5 for each curated gene using the 
MFAPreselection software we have developed (available in a Zenodo archive41). The 
archive describes the algorithm used by MFAPreselection to traverse pathway networks, 
dataflow within the program, and software code. MFA determines the relationship 
between GI50 and GE and/or CN data for all expressed genes as an angle that indicates 
the degree to which expression or copy number correlates either directly (~ zero degrees) 
or inversely (~180 degrees) with the GI50 of the set of cell lines.42,43 Circular plots, 
generated by MFAPreselection, indicate this correlation angle (Figure 1).43 
MFAPreselection searches for known gene pseudonyms and substitutes the correct alias 
(from www.genecards.org [downloaded July 2016]). In the Daemen et al. dataset5 used 
for training in SVM learning (see below), the microarray platform data was in some 
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instances labeled with conflicting gene names. During pathway extension, associated 
genes were related to older gene aliases that have been deprecated and reassigned by 
HUGO (Human Genome Organization) Gene Nomenclature Committee to other 
unrelated genes. This led to some spurious associations between genes during pathway 
extension. Examples include: PPY which was mismatched due to its former alias ‘PNP’ 
as well as DDR2 due to incorrect association with its former alias ‘TKT’. For the sorafenib 
model PE-Sor, associations of GC to CNN1 and CA3 were eliminated due to its original 
designation as ‘DBP’, however its associations between HNF1A, CYP11B1, CYP27B1, 
and PIK3R3 remained valid (Figure S1). This issue was addressed using a program script 
that removed these unsupported associations from the output of MFAPreselection.41 
 A Perl script was written to eliminate these spurious matches by confirming relations 
reported by MFAPreselection with the PathwayCommons Interaction SIF (Simple 
Interaction Format) file ("Parentage-MFA-Path-Source-Program.Simple-Output-
Version.pl"; provided in a Zenodo archive41). If corrected labels were not found or a gene 
was absent from a microarray platform, then this cell line or gene is not included in the 
analysis. 
ML signatures were expanded by MFAPreselection to include genes associated with 
curated genes by extension using components of adjacent biochemical pathways 
(pathway-extension, or PE; Figure S2). To identify these relationships, MFAPreselection 
relied on the PathwayCommons database (version 8 [downloaded April 2016]) to assess 
expanded gene lists by inclusion of genes addressable from the curated set (one node 
distant from a curated gene), followed by a second iteration (two nodes distant from a 
curated gene; illustrated in Figure 1). During this process, genes that did not meet 
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minimally-defined levels of MFA correlation to drug GI50 (either positive or negative) were 
discarded and additional gene expansion steps also ignored these genes. These levels 
were determined using six different conditions set for the MFAPreselection software: 
maximum thresholds up to 10° and 20° from either full direct or inverse correlation for 
curated genes only (conditions #1 and 2, respectively); up to a 10° and 20° threshold for 
both curated genes and directly related genes (one-node distant; conditions #3 and 4, 
respectively); and up to a 10° and 20° threshold for curated genes and genes up to two 
nodes distant from the curated gene set (conditions #5 and 6, respectively). Genes in 
which GI50 was correlated with CN (Tables S1 [A-F]) were not considered for SVM 
analyses due to unavailability of CN data in patient datasets.
2.3 SVM learning
Genes with expression levels correlated with GI50 were qualified for SVM analysis. SVMs 
were used to train GE datasets against GI50 data using the MATLAB statistics toolbox 
(similar to the procedure described in Mucaki et al. [2016]44 using SVM software 
developed in Zhao et al. [2018]40; software available at: doi:10.5281/zenodo.1170572). 
Instead of using the “fitcsvm” function (as in Mucaki et al. [2016]44), a multiclass-
compatible “fitcecoc” function was used to generate SVM signatures, with both 
misclassification rate44 and log loss40 value used as performance metrics to derive optimal 
signature models. A forward feature selection (FFS) algorithm was used to generate 
these gene signatures (program from Zhao et al. [2018]40: 
“FFS_strat_kfold_gridsearch.m”). FFS tests each gene at random from the qualified gene 
set by training a cross-validated Gaussian kernel SVM on the training data to determine 
the individual gene that produces the lowest misclassification rate or log loss value. 
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Subsequent genes are then added to determine whether model performance is improved, 
until the performance criterion converges to a minimum value. Models were built using a 
range of C and sigma values (from 1 to 100,000, in multiples of 10 for each variable 
[where C ≥ sigma]; 21 total combinations). Since the goal of pathway extension was to 
expand and improve these models beyond curated signatures with ≥ 2 genes, PE-derived 
gene signatures with fewer than two genes were excluded from proceeding to the 
validation step. 
2.4 Validation of Cell-Line Derived Gene Signatures using Patient Data
All derived multi-gene SVMs were validated against clinical patient data using traditional 
validation (MatLab program “regularValidation_multiclassSVM.m’ from Zhao et al. 
[2018]40). Performance was indicated by both overall predictive accuracy and by 
Matthews Correlation Coefficient (MCC, which assesses overall quality of a binary 
classifier by considering the balance of true and false positives and negatives). Overall, 
the best-performing gene signature for each drug was selected by MCC, as it is a metric 
not skewed by imbalanced data. Once the best performing SVM for each drug was 
established, leave-one-out cross-validation7 was used to determine the overall impact of 
each individual gene to the model itself (change in misclassification or log loss), as well 
as its impact on the accuracy of the model to predict chemotherapy response. Top-
performing PE TKI models can be accessed to predict responses based on expression in 
individual patients with our web-based SVM calculator 
(http://chemotherapy.cytognomix.com).6
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Ensemble averaging of multiple SVM models involved weighting patient predictions from 
highest performing models derived for a particular TKI by the area under the curve (AUC) 
of each corresponding model (computed using the MATLAB function ‘perfcurve’). MCC 
itself was also evaluated as a potential source of weights for ensemble averaging; 
however, AUC-weighted predictions were superior in overall performance. The number 
of models included in the ensemble varied, as the number of highest performance models 
for each TKI differed (4 for sorafenib; 2 for erlotinib, sorafenib, imatinib, sunitinib and 
gefitinib). A patient was considered resistant to a drug if the sum of all AUC-weighted 
predictions were > 0 and sensitive if this sum was < 0.
3. Results
3.1 Generating SVM signatures using breast cancer cell line-training data
Genes associated with drug response or function were curated for gefitinib (N=113), 
sunitinib (N=90), erlotinib (N=71), imatinib (N=157), sorafenib (N=73), and lapatinib 
(N=91) (curated genes are provided in Table S1 and labeled as ‘0’ node distant genes). 
In general, MFA was performed using 48 breast cancer cell lines using GE, CN and GI50 
values for each gene.5 Biochemically inspired ML-based signatures for each TKI, derived 
from curated genes, were obtained according to our previously described approach.6 
MFA analysis was also performed on genes encoding proteins related to these curated 
genes (through interaction or as neighbours in the same biochemical pathway) to identify 
those that also correlated, either directly or inversely, with GI50 (all GI50-correlated PE 
genes are provided in Table S1 [labeled as 1-node and 2-node distant genes]). This 
expanded set of GI50-correlating genes were then used to derive SVMs containing 
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combinations of curated and PE genes. The derived signatures for each TKI minimized 
either misclassification or log loss to generate the best performing models. The best 
performing curated and PE SVM signatures for erlotinib [C-Erl, PE-Erl], sorafenib [C-Sor, 
PE-Sor], gefitinib [C-Gef, PE-Gef], lapatinib [C-Lap, PE-Lap], imatinib [C-Ima, PE-Ima], 
and sunitinib [C-Sun, PE-Sun] are summarized in Table 1, whereas the performance of 
all models is indicated in Table S2. 
3.2 Validation of cell line-based SVM signatures using cancer patient data
Cell line-derived SVMs for TKIs were initially evaluated on patient data sets where 
patients were treated with the same agent.40 Erlotinib signatures were validated using 
patients with NSCLC (GSE61676; N=9 survived, 34 died), sorafenib signatures were 
validated using patients with hepatocellular carcinoma (GSE109211; N=21 sensitive, 46 
resistant), sunitinib signatures were validated using outcomes of patients with high-grade 
gliomas (GSE51305; N=6 sensitive, 12 resistant), imatinib signatures were validated 
using outcomes of patients with chronic myelogenous leukemia (GSE14671; N=17 
sensitive, 6 resistant), and lapatinib and gefitinib signatures were validated based on 
breast cancer outcomes (GSE66399 [N=8 survived, 23 died] and GSE33658 [N=10 
sensitive, 2 with resistant], respectively). 
MCC (range -1 to +1) was the primary determinant of model performance, as it measures 
overall accuracy (OA) while accounting for representation between binary prediction 
categories.45 This was necessary, as patient datasets available exhibited imbalances in 
the ratios of responsive to non-responsive patients in terms of their respective observed 
clinical outcomes. Models based on features generated under relaxed constraints 
Page 57 of 89 MedComm
For Review Only
14
(condition #6) generated the best performing SVM on patient data for every TKI, except 
sorafenib. The best-performing PE model was PE-Sor, which accurately predicted patient 
responses with 0.72 MCC (and 88% OA). The best performing curated model was Cur-
Lap, with 0.31 MCC (and 77% OA). In comparison to curated SVMs, PE SVMs predicted 
patient response with 0.26 higher MCC and 33% higher OA (13% increase in accuracy 
predicting sensitive patients; 13% increase in accurately predicting resistant patients). 
Except for imatinib, the best-performing PE model outperformed their curated 
counterpart. This difference in performance is evident in Figure 2, as predictive accuracy 
for PE models is consistently higher for both resistant and sensitive patient outcomes.
The erlotinib (GSE61676) and gefitinib (GSE33658) studies utilized for model testing 
provide patient GE data both pre- and post-treatment. This provided an opportunity to 
determine whether to determine whether short term drug exposure altered GE and model 
accuracy. For erlotinib, blood samples were obtained prior to and 24 hours post-
treatment. For gefitinib, biopsies were taken prior to and 3 weeks post-treatment. Both 
PE-Erl and PE-Gef exhibited slightly lower performance for the pre-treatment samples 
(Table S3), with 5 additional patients misclassified with PE-Erl (73% OA with N=43 total 
patients) and 2 additional misclassified individuals with PE-Gef (73% OA; N=12 patients). 
MCC for PE-Gef is significantly lower (-0.15), since the model misclassifies all untreated 
individuals as resistant. Treatment with these drugs perturbs predictions, but to a limited 
extent.
3.3 Composition of PE SVM signatures and contributions of individual features
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PE SVM signatures contain either genes from peer-reviewed literature about the drug 
response (“initial” or “curated” genes), those related to these genes through direct 
interactions or as neighbours within the same pathways (one-node distant genes), or 
genes associated with these one-node distant genes (two-node distant genes). To better 
comprehend the composition of and relationships between genes in the best-performing 
PE SVM signatures, we analyzed the connection networks for each model (see Table S4 
for connection network for all other top performing PE models). For example, while PE-
Sor consists of one curated gene and eight two-node distant genes, there are an 
additional 6 curated and 10 one-node genes that connect the genes in PE-Sor by 
pathway-extension (Figure 3A shows a two-dimensional visualized connection network 
for this drug; see Figures 3B-F for lapatinib, gefitinib, sunitinib, imatinib and erlotinib, 
respectively). Due to the complexity of the relationships between gene products 
for erlotinib, it was not feasible to create an unequivocal two-dimensional network 
diagram for this drug response, and is instead presented in tabular form (Figure 3F). 
Nevertheless, it is apparent from the majority of these network diagrams that genes that 
were two-nodes distant from the curated gene set were most commonly selected in the 
best performing PE models. Furthermore, the two-node distant genes selected interacted 
with multiple curated or one-node distant genes.
To determine the degree to which each gene in a signature contributed to the accuracy 
of the overall model prediction, we performed leave-one-out cross-validation for each 
gene in the best-performing model for each drug. We then reassessed the predictions of 
the resultant signature for the observed responses in the cell lines used for model training 
(Table S5) and for the patient data used for testing (Figure 4). Based on patient data, the 
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gene features eliminated from models that had the highest impact on performance were: 
CDK6, BAG2, SULT1E1, and IL1RN (PE-Erl); CNTN1, GCG and NTRK3 (PE-Gef); 
GRB7 and BCAT (PE-Lap); ELF5, TGFB1, PRKD2, RBP5, and GC (PE-Sor); EPHA2 
and SIAE (PE-Sun); and CACNA2D1 and GRM3 (PE-Ima). Genes removed that 
improved predictive performance on patient data included FBP1 (PE-Lap), PLAT (PE-
Sor) and LHX8 (PE-Sor).
PE-Gef consists of 4 pathway-extended genes (CNTN1, CXCL2, NTRK3 and GCG) and 
one curated gene, GCG. GCG encodes a hormone preprotein which is cleaved into four 
peptides, including glucagon-like peptide 2, which has been found to reduce gefitinib-
induced intestinal atrophy in mice.46 Removal of NTRK3 from PE-Gef had the largest 
impact on model performance, reducing MCC to 0. NTRK3 has a critical role in secretory 
breast cancer gene, with the EVT6-NTRK3 fusion oncogene being considered a primary 
initiating event.47,48 
PE-Sun, which consists of three pathway-extended genes, SIAE, NR4A1, and EPHA2, 
was evaluated in gliomas. NR4A1 is essential for colony formation of glioblastoma cells 
on soft agar.49 Of 14 glioblastoma specimens, 13 possessed elevated EPHA2 levels.50 
Removal of NR4A1 from PE-Sun did not alter overall accuracy or MCC of the model, 
while removal of EPHA2 decreased overall accuracy by 55% and MCC by 0.94. 
Regarding SIAE, alterations in cell surface sialylation by glucocorticosteroids has been 
suggested to promote glioma formation.51   
PE-Sor (COL25A1, TGFB1, DACT1, RBP5, PRKD2, GC, ELF5, LHX8, and SCNN1A) 
was used to predict sorafenib response in hepatocellular carcinoma (HCC) patients. 
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Removal of RBP5, PRKD2, GC and ELF5 significantly reduced overall accuracy (>50%) 
and MCC (>0.7) (Figure 4A). RBP5 is linked to aggressive tumour features in HCC,52 
PRKD2 is upregulated in HCC and correlated with metastasis,53 and decreased actin-free 
GC levels have been found to relate with disease severity in HCC.54,55 Vitamin D3, which 
is bound by GC, lowers the effective dose of sorafenib required for its cytostatic effect in 
melanoma and differentiated thyroid carcinoma.56 ELF5 has not been direct connected to 
HCC, but has been associated with a wide range of cancers.57,58 Genes in PE-Sor that 
have not been as strongly linked to cancer (COL25A1 and LHX8) did not change model 
accuracy to the same extent (<10%) when removed (Figure 4A). Removal of the curated 
gene TGFB1, which enhances the apoptotic activity and sensitizes cells to sorafenib59 
decreased overall accuracy by 60% in HCC patients. The respective contexts of the 
curated Sorafenib-related genes juxtaposed with the PE genes in PE-Sor are indicated 
in a cellular schematic of the roles and functions of these genes (Figure 5). 
PE-Ima (LIF, MRGPRF, GRM3, TNNI1, and CACNA2D1) predicted imatinib response in 
chronic myelogenous leukemia patients. LIF encodes a protein which prevents continued 
growth of myeloid leukemia cells by inducing terminal differentiation,60 although 
independent removal of LIF did not notably affect model performance. Downregulation of 
CACNA2D1 from PE-Ima is associated with erythroid differentiation of K562 and KCL-22 
chronic myeloid leukemia cells.61 Removal of CACNA2D1 decreased both classification 
accuracy and MCC (-44% and -0.18, respectively; Figure 4E). 
A second PE model (indicated in green in Figure 4E) exhibited comparable performance 
to PE-Ima: TNNI1 and WASF3 [C=10000, σ=10000], with an OA of 57% (47% accurate 
with sensitive and 83% with resistant patients; MCC = 0.27). WASF3 has been implicated 
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in breast cancer metastasis.62 TNNI1, a gene that is shared by both this model and PE-
Ima, is one of the three inhibitory subunits of smooth muscle troponin, that are all 
overexpressed in breast cancer.63 Interestingly, the kinase, TNNI3K, that phosphorylates 
this protein is essential for proliferation of mononuclear diploid cardiomyocytes during 
heart muscle repair due to injury.64 Phosphorylation of troponin would appear to have a 
previously uncharacterized moonlighting function in tumor development.65 If imatinib 
inhibits TNNI3K through an off-target effect, this may modulate TNNI1 activation and 
possibly, an associated proliferative phenotype. 
PE-Lap (FBP1, ITGA11, TRIM68, BCAT1, ZNF780A, UTP20, and GRB7) predicted 
outcomes of breast cancer patients treated with lapatinib. Independent removal of BCAT1 
reduced accuracy in predicting sensiti e patients. Silencing or knockdown of BCAT1 has 
been associated with reduced growth of triple negative breast cancer.66 Removal of 
ITGA11 or TRIM68 did not alter PE-Lap accuracy (Figure 4B). 
PE-Erl consisted of NEK7, SLCO3A1, RELB, FRMD4A, HSD17B2, CDK6, PALM, IL1RN, 
SMYD1, BAG2, GNG3, and SULT1E1, and was used to predict chemotherapy response 
in NSCLC patients. BAG2 and SULT1E1 are novel biomarkers of erlotinib efficacy, as 
removal of either gene led to imbalanced predictions of sensitive patients by this 
signature. Overexpression of BAG2 has been associated with poor disease-specific 
survival in lung cancer,67 while the SULT1E1 polymorphism rs4149525 has been 
associated with shortened overall survival in NSCLC.68 This model originally contained 
PLAT, which when eliminated from the erlotinib dataset of 43 patients significantly 
increased in overall accuracy (+10%) and MCC (+0.21) of the model predictions (Figure 
4F). PLAT was therefore considered a false positive result from ML, and therefore 
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eliminated from gene signature. Our post-hoc analysis demonstrated that the majority of 
genes (75%) in PE-Erl were associated with the NSCLC phenotype. 
3.4 Performance of PE SVM signatures on sex-stratified patients
Previous studies have suggested that females may be more sensitive to TKI treatment 
than males.69,70 We therefore stratified TKI model performance by sex in the GSE61676 
data set, which provided patient sex information along with response (19 male [3 
sensitive] and 24 female [6 sensitive] patients). Considering all patients, PE-Erl predicted 
patient response with an MCC of 0.41 and 83% overall accuracy (42% and 93% accurate 
in patients sensitive and resistant to this drug, respectively). In males alone, PE-Erl’s 
overall accuracy was lower (76%), with MCC notably decreased to 0.11, as PE-Erl did 
not predict individuals who were sensitive or resistant to the drug as accurately (27% and 
85%, respectively). In females, PE-Erl performed better than for the full data set, with 
85% OA (MCC = 0.56), of which resistance was predicted with 99% accuracy and 
sensitivity was predicted with 42% accuracy (Table S6). This indicates that the PE-Erl 
signature more precisely captures factors that contribute to greater sensitivity in females.  
The predictive performance of erlotinib PE model PE-Erl to the NSCLC dataset 
GSE61676 was higher in female patients than male patients (0.45 greater MCC; 9% 
greater OA). This was consistent with the possibility that PE-Erl contains gene(s) 
distinguishing sex-differentiated sensitivity to the drug. Of the 12 genes comprising PE-
Erl, independent removal of RELB and CDK6 features from the model notably reduced 
accuracy of the predicted response in female patients that were sensitive to the drug. 
RELB has previously been identified as a sex-discriminatory candidate gene in 
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trichostatin A-treated chronic lymphocytic leukemia cells due to repressed expression in 
resistant male cells, but upregulation in resistant female cells.71 RELB also possesses 
pro-survival functions across multiple cancer types72–74 and has been identified as a 
prognostic biomarker for NSCLC patients.75 Overall, RELB is a top candidate gene to 
explain the improved accuracy of PE-Erl in female NSCLC patients. 
3.5 AUC-weighted ensemble model predictions 
Ensemble learning consolidates hypotheses of multiple models to potentially improve 
predictive performance.76 For ensemble learning, each model’s AUC was computed and 
used to weigh predictions made for each model within the ensemble.77 There were 4 
SVMs for sorafenib possessing strong predictive accuracy with patient derived expression 
data. Therefore, all were used for ensemble averaging. For the other TKIs, ensemble 
learning combined the top- and second-best performing SVMs (Table 2). Ensemble 
averaging improved both OA and MCC for erlotinib (OA: 84% [+1%]; MCC – 0.45 [+0.04]), 
and sorafenib (OA: 91% [+3%]; MCC: 0.79 [+0.07]). For patients with the same predicted 
outcome in ≥75% of cases after ensemble learning, overall accuracy exceeded 80% for 
all TKIs except lapatinib. Discordant consensus predictions between multiple signatures 
for the same drug (majority outcome occurred <75% for each patient) exhibited lower 
overall accuracy. 
4. Discussion 
Pathway-extended GE signatures generally improved accuracy of predicted patient 
responses to specific TKIs. Compared to signatures comprised solely of literature curated 
genes, PE signatures revealed previously unknown gene loci that contributed to drug 
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response and, on average, had consistently better predictive performance. Aside from 
higher OA, the prediction accuracy for both sensitive and resistant patient groups 
(measured by MCC) was consistently more balanced. For example, Cur-Lap was the 
sole curated model with higher OA than its PE counterpart; however, its predictions were 
more skewed resulting in lower MCC. Furthermore, both MCC and overall accuracy were 
increased by AUC-weighted ensemble averaging of multiple PE models for sorafenib, 
erlotinib and imatinib. Except for lapatinib, the highest OAs were evident in patients 
receiving a ‘consensus’ prediction (where ≥75% of predictions made by the models in the 
ensemble predicted the same outcome for a patient). The improved predictive 
performance of PE SVMs, both individual and as ensembles of models, suggests that the 
genes within these signatures may refine the predominant mechanisms of both sensitivity 
and resistance to TKI therapy. PE gene models may be more useful in selecting 
chemosensitivity regimens for patients compared to models solely consisting of 
previously implicated genes known to respond to a specific chemotherapy. 
Pathway-extension and the inclusion of pathway-related genes allowed for a larger pool 
of genes involved in ML. We avoided overfitting78 by pre-filtering these genes based on 
correlation with GI50. Furthermore, independent validation was determined by the identity 
and expression level of these features in patients treated with these drugs. Signatures 
containing pathway-related genes produced higher performing SVM signatures, 
consistent with the possibility that optimal molecular indicators of chemo-response may 
identify genes upstream or downstream of, or are interactors with, previously known 
cancer biomarkers. Generating SVMs from curated genes assures that features selected 
do not arise from statistical association alone. Generating PE SVMs required systematic 
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selection of genes with established relationships to curated genes. For the best-
performing PE gene signatures, most signature genes validated in the present study had 
been independently associated with abnormalities of expression, copy number or 
mutation in these tumour types (Additional References). Expanded signatures could 
potentially assist in the identification of novel biomarkers of chemo-response in these 
tissues.
Primary and secondary genes in PE gene signatures can offer context for drug responses 
without predicate literature support. The relationships between curated genes and genes 
selected through pathway-extension for sorafenib are illustrated in Figure 5. The vitamin 
D transporter encoded by GC is a major determinant of the response to this drug, as 
overall prediction accuracy is decreased by 52% upon its removal from PE-Sor (Figure 
4A). In fact, GC is two nodes distant from multiple curated genes (ABCB1, ABCC2 and 
HNF1A, among others [Figure 3A]). The ABCB1 transporter has been implicated in 
sorafenib-related toxicities based on efflux efficiency.79,80 ABCB1 also carries out efflux 
of Vitamin D3,81 and the 1,25-dihydroxy-vitamin D3 isoform (or 1.25D) activates ABCB1 
expression.82 Vitamin D is converted to this 1.25D isoform by CYP27B1, which is one-
node distant from ABCB1. Similarly, GC binds specifically to 1.25D, which puts GC one 
node distant from ABCB1. The growth inhibitory effect of sorafenib has been shown to be 
amplified by 1.25D.56 Together, these network connections provide context that integrates 
functions and roles of individual genes of the tumour response to sorafenib. The PE 
signatures will be useful for understanding drug toxicity, although it was not explicitly a 
goal of this study. The importance of GC in PE-Sor may explain why a lower sorafenib 
dose is effective for treatment. Supplemental vitamin D3 reduces toxicity to sorafenib at 
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this lower dose in differentiated thyroid carcinoma that is non-responsive to iodine 
therapy.56 
The best performing SVMs for TKIs shared several common genetic pathways. Multiple 
PE models contained genes related to NOD-like receptor signaling (erlotinib: NEK7, 
RELB), PI3K-AKT signaling pathway (erlotinib: CDK6, GNG3; lapatinib: ITGA11; 
sunitinib: EPHA2, NR4A1) and Ras-Raf-MEK-ERK pathway (erlotinib: CDK6, RELB; 
sorafenib: TGFB1; sunitinib: EPHA2, NR4A1). Aberrant NOD-like receptor signaling 
drives carcinogenesis,83 while numerous cancer therapies target either or both of PI3K 
and AKT.84–86 The Ras-Raf-MEK-ERK pathway involves several protein kinases activated 
by tyrosine kinase receptors, with oncogenic mutations most prominently affecting Ras 
and B-Raf within the pathway.87 These pathways, which are disrupted broadly among 
different cancers, are implicated across numerous high performing ML models predicting 
TKI response.
Several pathway-extended (EPHA2, PRKD2, and PDGFRB) and curated (CDK6 and 
ABL2) gene products extrapolated from the highest performing signatures were bound to 
kinases based on a proteomic analysis of target selectivity for 243 kinase-inhibitors on 
259 distinct tyrosine kinases.88 Few tyrosine kinase target genes from this proteomic 
analysis for TKIs in the current study exhibited correlations between GI50 and either gene 
expression or copy number (< 20° threshold; Table S7). RET was the only SVM gene 
implicated in the response to a TKI for both gene expression and protein (sorafenib; 
Concentration- and Target-Dependent Selectivity of 0.515; Klaeger et al. [2017]88). 
Therefore, expression of genes that are either positively or inversely correlated with drug 
response is generally unrelated to quantification of proteins that directly interact with the 
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kinases themselves. If absence of signature genes from those corresponding to 
proteomic analysis is not attributable to either experimental or specific cell lines used, 
then signature gene expression is more likely indirectly regulated by gene products that 
are selective for most TKIs. Many genes in the PE SVMs were two nodes distant from 
curated biomarkers, which is consistent with the possibility that these represent common 
control points in the regulation of drug responses. In this regard, such control points 
exhibit behavior similar to state-cycle attractors of self-organizing systems.89 From a ML 
perspective, the dimensionality of the SVM model is reduced, avoiding overfitting, by 
substituting these control point genes for curated genes. Improvement in the prediction 
accuracy for both the sensitive and resistant patient categories might also be a 
consequence of these biomarkers being control points for multiple curated genes. 
Consider two curated genes that are "controlled" or regulated by the same two node 
biomarker, where inclusion of one of these improves accuracy for detecting drug 
sensitivity, and the other improves detection of resistance. Substituting the controlling 
gene for both curated genes in the PE-signature might improve accuracy of detection of 
both outcomes.  
Transferability of these cell line-based models to other independent cell line datasets was 
also evaluated.90 PE TKI models were analyzed using data from the Sanger Genomics of 
Drug Sensitivity in Cancer Project (GDSC), including RNA-seq derived cancer cell line-
derived gene expression data (E-MTAB-3983; ArrayExpress) based on IC50 values of cell 
lines in CancerRxGene.91 Using median IC50 to distinguish sensitivity from resistance, the 
top SVM that we derived for each TKI could not significantly separate cell lines sensitive 
and resistant to the same drug in GDSC (MCC from 0 to 0.19; OA ranging from 50-58%). 
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Altering the IC50 thresholds did not significantly change these results. Applying this 
analysis to cell lines from specific tissues used in the derivation of the specific TKI 
signatures, PE-Ima was more accurate for seven imatinib-treated cell lines derived from 
intestinal tumours (OA of 69%; MCC – 0.41). The disparity in performance between the 
training and testing data sets may be related to differences in the expression patterns in 
different tissue types, or batch effects. IC50 measurements for the same cell line and drug 
are known to vary significantly between studies, especially when the cell line is drug 
insensitive,92 which may contribute to the poor correlation between results of both 
datasets. 
Transferability of SVMs to different patient datasets may also be confounded by several 
other limitations of applying ML models derived from cell line expression to predict 
responses to the same drugs using patient GE data. By contrast with tumours, cancer 
cell lines tend to have a stable genetic profile when grown under controlled culturing 
conditions. Consequently, they tend to lack the genetic heterogeneity present in many 
tumour types,93 particularly during progression, which often occurs concomitant with 
evolution of acquired chemotherapy resistance.94 Cancer cell lines also lack extracellular 
matrix, which contributes to tumour growth, migration and invasion in vivo. These 
differences may challenge prediction accuracy of cell line-based SVMs using patient GE 
and/or CN. Clinical outcome measures within patient data sets were not consistent 
between different studies of the same tumour type. Finally, the cell line GE data used for 
training originated in this study solely from breast cancer, whereas patient tumour GE 
data were also derived from other cancer types. 
5. Conclusions
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The enhanced performance of chemotherapy response models developed using 
pathway-extension (over curated-only models) suggests that an interaction between a 
drug and its target may not directly relate with drug response; sensitivity could also be 
caused by a cellular event downstream of the drug-target interaction. PE models derived 
in this study demonstrated strong efficacy in selecting relevant genes, identifying novel 
molecular biomarker candidates, and predicting patient responses to TKIs. Strong-
performing PE models appear to predict chemotherapy response in a cancer-type specific 
fashion, as many pathway-related genes selected by SVM software as novel candidate 
biomarkers of TKI efficacy were already prognostic biomarkers for the cancer type 
patients within the testing set were afflicted with. Ensemble averaging of multiple PE 
SVMs improved predictive accuracy in most cases and were found to be most commonly 
correct when predictions were highly consistent across each model constituting the 
ensemble. PE-Erl was also shown to have greater accuracy when considering solely 
female NSCLC patients. Interestingly, RELB, a feature in this signature, had previously 
demonstrated sexually dimorphic expression upon cancer treatment. The process of 
including pathway-related genes in biochemically inspired gene signatures can produce 
highly specific and accurate SVMs. PE models may have practical value, both in 
identifying novel biomarkers of chemosensitivity and in selecting effective 
chemotherapeutic agents. 
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Table 1. Performance of Curated SVMs and PE Models on Training and Patient Testing Data
Validation TrainingTKI
(Patient Tumor Type; 
GEO Dataset)
Model Gene Signature (SVM: C; σ)
MCC Sensitive Resistant Overall Log Loss Misclass-ification




NEK7, SLCO3A1, RELB, FRMD4A, HSD17B2, 
CDK6, PALM, IL1RN, SMYD1, BAG2, GNG3, 
SULT1E1 (1000; 100)
0.41 42% 93% 83% 0.01 -




ELF5, RBP5, GC, PRKD2, SCNN1A, 
COL25A1, TGFB1, DACT1, LHX8 (100000; 
1000)
0.72 72% 95% 88% 0.05 -
Cur GRP (10000; 10) 0.16 13% 100% 29% 0.53 -Gefitinib
(Breast Cancer; 
GSE33658) PE CNTN1, CXCL2, NTRK3, GCG (10000; 10) 0.67 100% 50% 91% 0.58 -
Cur ERBB2 (10000; 1) 0.31 13% 100% 77% 0.72 -Lapatinib
(Breast Cancer;
GSE66399) PE
FBP1, ITGA11, TRIM68, BCAT1, ZNF780A, 
UTP20, GRB7 (10; 10) 0.33 63% 74% 71% 0.01 -
Cur IL3, ABL2, CDKN1A (10000; 10) 0.23 41% 83% 52% - 0.42Imatinib
(Leukemia; 
GSE14671) PE
LIF, MRGPRF, GRM3, TNNI1, CACNA2D1 
(100000; 100) 0.18 84% 33% 70% - 0.06
Cur HGF, VEGFC, TSC1, AXL, ENPP2, NFKB1 (100000; 10000) 0.31 87% 45% 59% - 0.14
Sunitinib
(Glioma;
GSE51305) PE EPHA2, NR4A1, SIAE (100000; 100000) 0.61 67% 92% 83% - 0.20
Cur - Curated models derived from genes associated with drug in literature; PE - Pathway-extended models; MCC - Matthews Correlation 
Coefficient; Sensitive - Accuracy to Drug Responsive Patients; Resistant - Accuracy to Non-Responsive Patients; Overall - Combined accuracy
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Table 1 - Performance of Curated SVMs and PE Models on Training and Patient Testing Data. Curated 
and PE SVMs were derived for each TKI based on ability sorting cancer cell lines. The C (box-constraint), 
σ (kernel-scale) and features comprising the best-performing model are indicated. Models listed are those 
which exhibited optimal performance, defined as the model with the highest MCC against the patient data 
set. ‘Validation’ indicates the predicted drug response of patients made by each curated and PE model as 
compared to the observed response provided by these studies. ‘Training’ indicates either percent 
misclassification or overall log-loss of the cell line-based model by cross-validation, depending on which 
minimization metric was used in said model derivation.
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Table 2. Models used in the Ensemble Averaging analysis of Patient Data
TKI Gene Signatures (SVM: C; σ) AUC MCC Sensitive Resistant Overall Consensus† Non-consensus†
1. NEK7, SLCO3A1, RELB, FRMD4A, HSD17B2, CDK6, 




2. RET, HDGF, B3GNT5, BAG2, DSP, CAPN1, MAF, 
BCL2, MAP2K6, RPL13A, PTPRZ1, OLIG2 (10000; 100) 0.47
0.45 44% 94% 84% 89% 57%
1. ELF5, RBP5, GC, PRKD2, SCNN1A, COL25A1, TGFB1, 
DACT1, LHX8 (100000; 1000) 0.88
2. ELF5, RBP5, GC, PRKD2, SCNN1A, GRM7, COL25A1, 
TGFB1, DACT1, LHX8 (100000; 1000) 0.85
3. CPT1C, DOPEY2, KRT26, DGUOK, DLC1, CYP11B1, 




4. FURIN, HTR3D, LAMA1, STMN2, SLITRK3, CACNA1S, 
SCN2A, CCL5, TRIM32 (100000; 100000) 0.93
0.79 81% 96% 91% 94% 83%
1. FBP1, ITGA11, TRIM68, BCAT1, ZNF780A, UTP20, 
GRB7 (10; 10) 0.70
Lapatinib
2. S100A12, API5, GRHL1, TAS1R1, TUBB1, CORO1A 
(100000; 100) 0.56
0.33 63% 74% 71% 55% 80%
1. EPHA2, NR4A1, SIAE (100000; 100000) 0.78Sunitinib
2. SCN3B, MED29, MPST, TSC1, AHR, CARD9, RPL3 
(100000; 100000) 0.79
0.40 83% 58% 67% 91% 29%
1. LIF, MRGPRF, GRM3, TNNI1, CACNA2D1 (100000; 
100) 0.55
Imatinib
2. WASF3, TNNI1 (10000; 10000) 0.65
 0.27 47% 83% 57% 85% 20%
1. CNTN1, CXCL2, NTRK3, GCG (10000; 10) 0.5Gefitinib
2. BDNF, PRKCB (10000; 100) 0.69
0.39 89% 50% 82% 100% 33%
† Consensus and non-consensus predictions are when the Ensemble predicts the same outcome for a patient ≥ or <75% of the time, respectively
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Table 2 - Models used in the Ensemble Averaging analysis of Patient Data. Ensemble averaging 
amalgamates predictions from numerous SVMs for an individual TKI, weighted by AUC (indicated). Each 
SVM signature included within ensemble averaging predicted the response of each patient treated with its 
associated TKI, and the majority prediction was used of that of the ensemble. Overall, the accuracy of the 
ensemble prediction was equivalent to or greater than any individual model within it.




Figure 1 – Procedure for Pathway Gene Selection. An initial set of genes with known 
associations to a particular TKI (here we show a subset of sorafenib-related genes) are selected 
and then evaluated by MFA, which was used to find a correlation between cell line drug sensitivity 
(GI50) and the GE or CN of these genes in those cell lines (left). MFA correlation circles visualize 
these relationships (bottom). The gene list is extended, using pathway and interaction databases 
(i.e. PathwayCommons) to find genes related to curated genes which showed MFA correlation to 
GI50 (one-node distant genes; middle-left). The list is extended again from the MFA-correlating 
one-node distant genes (two-node distant genes; middle-right). All curated and extended genes 
which showed an MFA correlation were then used as features to generate a final predictive SVM 
gene signature for the evaluated TKI (right). Genes within the best performing sorafenib signature 
are indicated in thick borders (black for curated genes, purple for pathway-extended genes).
 
Figure 2 - Accuracy of Curated and Pathway-Extended SVMs on TKI Sensitive and 
Resistant Patients. The predictive accuracy of the best-performing curated (C-) and Pathway-
Extended (PE-) models for each TKI were arranged based on their accuracy in classification of 
drug sensitive and resistant tumour patients. This illustrates how curated models are often only 
accurate towards one patient class (sensitive or resistant) but not both (red), which is an issue as 
the patient data was often imbalanced (number of sensitive | resistant patients in each study: 
lapatinib [‘Lap’; n= 8 | 23], imatinib [‘Ima’; n= 17 | 6], sunitinib [‘Sun’; n= 6 | 12], erlotinib [‘Erl’; n= 
9 | 34], gefitinib [‘Gef’; n= 10 | 2], and sorafenib [‘Sor’; n= 21 | 46]). Conversely, predictions by PE 
SVMs were often more balanced (blue), possessing moderate to high accuracy for both sensitive 
and resistant patients, and consequently greater accuracy as a whole. 
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Figure 3 - Connection Network for Pathway-Extended TKI SVMs. Schematic relationships 
outlining the pathway connections for the best-performing PE model for each drug in panels A) 
sorafenib; B) lapatinib; C) gefitinib; D) sunitinib; E) imatinib and F) erlotinib. All symbols indicated 
are gene names. The erlotinib model was highly interconnected and is represented as a table. 
Genes in red are features selected for the final PE-Sor gene signature, while genes colored green 
were chosen in a separate PE gene signature with comparable performance. Genes in black were 
not part of the final signature themselves but correlated with efficacy to sorafenib by MFA and 
expanded the gene pool through biochemical connections they possessed to one-node or two-
node distant genes.
Figure 4 – Effect of Removal of Individual Genes from Signature on Overall Accuracy using 
Patient Tumour Data. The patient classification accuracy and MCC of the strongest performing 
PE models are altered upon the removal of each component gene listed. These PE TKI gene 
signatures are: A) sorafenib [PE-Sor]; B) lapatinib [PE-Lap]; C) gefitinib [PE-Gef]; D) sunitinib 
[PE-Sun]; E) imatinib [PE-Ima]; and F) erlotinib [PE-Erl]. Blue and red bars denote the overall 
accuracy and MCC of the model after gene removal, respectively. 
Figure 5 –Schematic of the Pathway-Extended Genes in the Sorafenib Model PE-Sor. The 
best performing sorafenib model PE-Sor is a 9-gene model consists of a single curated gene 
(TGFB1) and eight genes selected by pathway-extension (ELF5, RBP5, GC, PRKD2, SCNN1A, 
COL25A1, DACT1, and LHX8). This cell schematic provides context of the cellular mechanisms 
of action and/or known relationships between genes with a documented impact on sorafenib 
activity (‘curated’ genes; black borders) and those genes selected by pathway extension (purple 
borders). Genes with grey borders are not curated nor pathway-extended genes and are simply 
present to give context between genes and their known cellular functions. Thicker borders specify 
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those genes in the PE-Sor model, while gene colour-coding indicates how GE and/or copy 
number correlated to sorafenib GI50 by MFA.
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Figure 1 – Procedure for Pathway Gene Selection. An initial set of genes with known associations to a 
particular TKI (here we show a subset of sorafenib-related genes) are selected and then evaluated by MFA, 
which was used to find a correlation between cell line drug sensitivity (GI50) and the GE or CN of these 
genes in those cell lines (left). MFA correlation circles visualize these relationships (bottom). The gene list is 
extended, using pathway and interaction databases (i.e. PathwayCommons) to find genes related to curated 
genes which showed MFA correlation to GI50 (on -node distant genes; middle-left). The list is extended 
again from the MFA-correlating one-node distant genes (two-node distant genes; middle-right). All curated 
and extended genes which showed an MFA correlation were then used as features to generate a final 
predictive SVM gene signature for the evaluated TKI (right). Genes within the best performing sorafenib 
signature are indicated in thick borders (black for curated genes, purple for pathway-extended genes). 
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Figure 2 - Accuracy of Curated and Pathway-Extended SVMs on TKI Sensitive and Resistant 
Patients. The predictive accuracy of the best-performing curated (C-) and Pathway-Extended (PE-) models 
for each TKI were arranged based on their accuracy in classification of drug sensitive and resistant tumour 
patients. This illustrates how curated models are often only accurate towards one patient class (sensitive or 
resistant) but not both (red), which is an issue as the patient data was often imbalanced (number of 
sensitive | resistant patients in each study: lapatinib [‘Lap’; n= 8 | 23], imatinib [‘Ima’; n= 17 | 6], sunitinib 
[‘Sun’; n= 6 | 12], erlotinib [‘Erl’; n= 9 | 34], gefitinib [‘Gef’; n= 10 | 2], and sorafenib [‘Sor’; n= 21 | 46]). 
Conversely, predictions by PE SVMs were often more balanced (blue), possessing moderate to high accuracy 
for both sensitive and resistant patients, and consequently greater accuracy as a whole. 
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Figure 3 - Connection Network for Pathway-Extended TKI SVMs. Schematic relationships outlining 
the pathway connections for the best-performing PE model for each drug in panels a) sorafenib; b) lapatinib; 
c) gefitinib; d) sunitinib; e) imatinib and f) erlotinib. All symbols indicated are gene names. The erlotinib 
model was highly interconnected and is represented as a table. Genes in red are features selected for the 
final PE-Sor gene signature, while genes colored green were chosen in a separate PE gene signature with 
comparable performance. Genes in black were not part of the final signature themselves but correlated with 
efficacy to sorafenib by MFA and expanded the gene pool through biochemical connections they possessed 
to one-node or two-node distant genes. 
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Figure 4 – Effect of Removal of Individual Genes from Signature on Overall Accuracy using 
Patient Tumour Data. The patient classification accuracy and MCC of the strongest performing PE models 
are altered upon the removal of each component gene listed. These PE TKI gene signatures are: a) sorafenib 
[PE-Sor]; b) lapatinib [PE-Lap]; c) gefitinib [PE-Gef]; d) sunitinib [PE-Sun]; e) imatinib [PE-Ima]; and f) 
erlotinib [PE-Erl]. Blue and red bars denote the overall accuracy and MCC of the model after gene removal, 
respectively. 
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Figure 5 –Schematic of the Pathway-Extended Genes in the Sorafenib Model PE-Sor. The best 
performing sorafenib model PE-Sor is a 9-gene model consists of a single curated gene (TGFB1) and eight 
genes selected by pathway-extension (ELF5, RBP5, GC, PRKD2, SCNN1A, COL25A1, DACT1, and LHX8). This 
cell schematic provides context of the cellular mechanisms of action and/or known relationships between 
genes with a documented impact on sorafenib activity (‘curated’ genes; black borders) and those genes 
selected by pathway extension (purple borders). Genes with grey borders are not curated nor pathway-
extended genes and are simply present to give context between genes and their known cellular functions. 
Thicker borders specify those genes in the PE-Sor model, while gene colour-coding indicates how GE and/or 
copy number correlated to sorafenib GI50 by MFA. 
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